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23rd of October, 2017 
 
 
Gabriele Missale 
Associate Editor 
 
Mario U Mondelli 
Editor-in-Chief 
Liver International 
 
 
Dear Professor Gabriele Missale, 
Dear Professor Mario U Mondelli, 
 
Please find attached the revised version of our manuscript entitled: Functional 
polymorphisms of innate immunity receptors are not risk factors for the non-SBP type 
bacterial infections in cirrhosis" (Manuscript ID: LIVint-17-01007.R1).  
 
We are grateful to the reviewers for their in-depth and important comments as well as for the 
critiques that helped improving the manuscript. We revised the manuscript according to the 
concerns raised and inserted relevant additional information in the main text of the 
manuscript. Some information was also added to Supplementary Material. Following the 
valuable proposed changes by the Reviewers, we included more detailed descriptions and 
completely new data as well. Despite concision of the Section of Discussion,  with the 
insertion of these significant pieces of information, and the 5 requested additional literature 
references the length of the manuscript exceeds the limits of the Journal to a minor degree 
(The original version of the manuscript was already close to limits of the Journal, 4936 
words). We hope that these new data significantly enhance the overall quality of our research. 
We feel that the size of the article is still within the range that can keep the attention of the 
readers and sincerely hope that it is still acceptable for the Journal, even though it is slightly 
over of the official limits (5419 words instead of 5000, which includes 5 additional requested 
references). 
 
Professional English editing requested by Associate Editor was also performed.  
UNIVERSITY OF DEBRECEN 
FACULTY OF MEDICINE 
INSTITUTE OF INTERNAL MEDICINE 
DEPARTMENT OF GASTROENTEROLOGY 
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2 
Reviewer 1 
Major points 
 
Comment 1:“Please indicate the power of the study according to previous frequencies of 
bacterial infections in cirrhosis and the expected MAF in cirrhotic patients.  Given the 
multiplicity of genetic associations tested here, the relatively low number of infections, I 
would expect the study to be somewhat underpowered.” 
 
Mean allele frequencies (MAF) in our study are similar to those reported in Caucasian cohorts 
[Lek M. et al, Nautre 2016]. In our study, the probability of bacterial infections was 49.6 ± 4.1 % 
(Kaplan-Meier estimate ± SE) during the follow up period (median, IQR: 32 [12-60] months). 
This rate of infections is similar to those in previous reports [Nahon P. Gut, 2017;66(2):330-341. 
doi: 10.1136/gutjnl-2015-310275., Borzio M. et al. Digest Liver Dis 2001;33:41-8 ].  
We did not perform a sample size calculation or power analysis in the design phase of the 
study that is a limitation to acknowledge. According the request of the Reviewer 1 we 
performed a post-hoc power analysis in Stata (v13.0). The following factors were considered 
in the analysis:  
- sample size: 243 
- allele frequencies (NOD2 risk variant present: 15%, TLR2 (T-16934A) TT present: 
25%, TLR4 (D299G) AG risk variant present: 7%)  
- Cumulative probability of bacterial infections in control group: 40% 
- Clinically relevant hazard ratio: 2 
- type I error: 0.05, two-sided 
 
We found that the power associated with NOD2, TLR2 and TLR4 for detecting a difference in 
the development of bacterial infections were 89.2%, 95.6% and 67%, respectively. 
 
Command syntax for power analysis was the following: 
stpower logrank 0.6, n(243) hratio(2) p1(0.85 0.75 0.93) table columns(p1 power) 
 
Regarding TLR4 polymorphism we mentioned this limitation in the Discussion section Page 
20. 
“The limitation of the present study is that the association of bacterial infections and 
TLR4 polymorphisms warrants further evaluation in a larger cohort since our study 
was underpowered to detect such an association at this sample size (Supplementary 
Table 1).”  
 
 
Comment 2: “The majority of infections are UTIs – UTIs (as well as erysipelas) are unlikely 
to be influenced by intestinal BT via NOD2 and are often asymptomatic in cirrhotic patients. I 
would suggest performing sensitivity analyses for spontaneous infections (SBP, spont. 
bacteremia, empyema), infections excluding UTI, skin infections, gastroenteritis and skin 
infections, and severe infections requiring hospitalisation. How many patients were treated 
with antibiotics?” 
 
We agree with both concerns of the Reviewer 1. that (1) UTI and skin infections are usually 
less severe than spontaneous infections, like SBP in cirrhosis, and (2) intestinal BT is also not 
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3 
a major contributor in the development of these infections. The rational why we considered 
evaluating non-SBP type bacterial infection of various locations altogether instead excluding 
some of their types were the followings:  
 In cirrhosis, UTIs are important and often solely precipitating factors of hepatic 
encephalopathy [Strauss E, et al. Hepatogastroenterology. 1998 May-Jun;45(21):900-4.] and can 
be the source of bacteraemia as well. Furthermore, the presence of UTI indicated an increased 
risk of 90-day mortality in patients with advanced cirrhosis [Reuken PA, et al. Liver Int. 2013 
Feb;33(2):220-30. doi: 10.1111/liv.12029.]  
 In case of skin and soft tissue infections GPC, are the most prevalent pathogens, but 
Enterobacteriaceae and anaerob bacteria can also be the pathogens of these infections 
[Christou L, et al. Am J Gastroenterol. 2007 Jul;102(7):1510-7.] GNB (Escherichia E. coli, Klebsiella 
K. pneumoniae) should also be considered as potential etiologic agents. In these latter cases, 
supposedly, the source of the bacteria is the gut itself. As a result of BT, enteric bacteria reach 
the systemic circulation, cause bacteraemia and seed the tissues of the extremities [Chang CM, 
et al. Infection. 2008 Aug;36(4):328-34. doi: 10.1007/s15010-008-7272-3.]. The course of GNB cellulitis 
is usually rapid and can be fatal. Progression to septic shock is common [Horowitz Y, et al. Gram-
negative cellulitis complicating cirrhosis. Mayo Clin Proc. 2004 Feb;79(2):247-50.]. 
 Finally, SBP can also occur in asymptomatic cirrhotic outpatients. [Cadranel JF, et al. 
World J Hepatol. 2013 Mar 27;5(3):104-8. doi: 10.4254/wjh.v5.i3.104. and Mohan P, et al. Indian J 
Gastroenterol. 2011 Sep;30(5):221-4. doi: 10.1007/s12664-011-0131-7.]  
 
Subgroup analysis of spontaneous infections - that were SBPs - however, were reported in 
detail in Page 13 (Section of Results – Risk factor of SBP) and Figure 4, acknowledging that 
intestinal BT is important process in the development of spontaneous infections in cirrhotic 
patients.  
 
The pathogenic point of view why we considered it important to evaluate potential association 
of PRR gene variants with bacterial infections beyond SBP were the followings: (1) there is a 
universal function of PRR in innate host defense (detailed in Section of Discussion) (2) there 
are reports of association of functional polymorphisms of PRRs with systemic infections in 
various patients groups, which are devoid of pathologic intestinal BT.  
 
 We also accept the important remark of the Reviewer 1 that it is worthy of evaluating 
the association of PRR variants with bacterial infections according to severity of infection. In 
Section of Patients and Methods – Study design (Page 7) we stated “Outpatients at inclusion 
(n=243) were enrolled into an observational follow-up study where the attending 
gastroenterologist registered date and type of bacterial infection (BI) warranting hospital 
admission (diagnostic criteria are summarized in Supplementary Material) and development 
of disease specific complications (ascites, hepatic encephalopathy or variceal bleeding) 
during regular and extraordinary outpatient follow-up visits and inpatient stays 
prospectively.” This approach was really similar that was applied by Senkerikova R, et al. (J 
Hepatol.  2014 Apr;60(4):773-81. doi: 10.1016/j.jhep.2013.12.011). Based on these criteria, 
evaluated infectious episodes in the present cohort can be considered clinically significant 
bacterial infections. Concerning that local and systemic host defence mechanisms are 
compromised and local infections can easily be disseminated, all patients with a proved 
bacterial infection were treated with empiric antibiotic regimen and adjusted according to 
microbiologic results if it was necessary. Nevertheless, we are aware of the limitations of this 
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4 
definition as well. In the clinical practice when we face the acute deterioration of a patient 
with cirrhosis (episode of acute decompensation) with simultaneously diagnosed bacterial 
infection, it is difficult somehow to decide whether bacterial infection is a coincident 
problem/ complication or has a real causative effect.   
  
In the revised version of the manuscript to be able to evaluate severity of bacterial infections, 
we determined infection-related mortality and its association with PRR gene variants. None of 
the examined PRR gene variants were associated with the risk of death during a subsequent 
bacterial infection.  
 
We added these results into the Section of Functional polymorphisms of PRR genes and a new 
table into the Supplementary Material. None of the pattern recognition receptor gene variants 
were associated with the risk of death. 
 
Supplementary Table 2. Infection-related mortality in cirrhosis according to NOD2 risk alleles 
(L1007fsinsC -/C, R702W C>T or G908R G>C) (A) and TLR2 (T-16934A) (B) or TLR4 
(D299G) (C) polymorphisms after the first bacterial infectious episode (n=85). 
 
 Binary logistic regression analysis 
 30-day 90-day 
 OR 95% CI P-value OR 95% CI P-value 
NOD2 polymorphism 
(present) 0.14 (0.02-1.1) 0.061 0.24 (0.05-1.14) 0.073 
 
TLR2 
TT Ref.  0.804 Ref.  0.352 
TA 0.67 (0.2-2.22) 0.509 0.43 (0.13-1.37) 0.153 
AA 0.85 (0.27-2.63) 0.773 0.64 (0.22-1.88) 0.414 
TLR4 (AG) 4.07 (0.83-19.84) 0.082 3.13 (0.65-15.11) 0.155 
OR: Odds ratio 
 
 
Comment 3: “How were genotyping experiments validated? I would suggest sequencing of 
PCR products for a subset of samples to prove that FRET genotyping is valid. Especially for 
rs4986790 as it is done by in-house primers. Alternatively you could show representative 
melting curves as supplemental material.” 
 
For rs4986790 experiment synthesis primers were designed in-house, while FRET 
oligonucleotides were similar to Hamann et al. (J Immunol Methods. 2004 Feb 15;285(2):281-91. 
PubMed PMID: 14980441.) Representative melting curve genotyping results performed on a 
LightCycler 480 system and now it is shown in the Supplementary Figure 1.  We modified the 
Section of the Results – Gene analysis of NOD2, TLR2 and TLR4 (Page 8 and Page 9) and 
Supplementary Material accordingly. 
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5 
Figure 1. Representative melting curve genotyping results performed on a LightCycler 480 system. 
NTC= "no template control” 
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7 
Comment 4: “The discussion needs to be more concise and needs to recognize current 
investigations showing no association of NOD2 with SBP in large cohorts (Lutz et al. Dig 
Liver Dis. 2016. Bruns et al. Sci Rep 2017), association of NOD2 with BT (Harputluoglu Dig 
Dis Sci 2016, Bruns et al Dig Dis Sci 2016), the association of TLR4 with infections in 
cirrhosis (published in AP&T several years ago).” 
 
We took shortcut some degree the original version of the Discusssion section and added the 
suggested literature findings to the pertinent part.  
 
Regarding SBP (Page 16 and 17):  “Similar to most of the previous studies [8–10], the 
presence of NOD2 allele variants was a risk factor for SBP in our cohort as well. A recent 
large association study in patients with decompensated cirrhosis so far did not 
demonstrate a role of NOD2 variant in mediating susceptibility for SBP. (Mai M, et al. 
Sci Rep. 2017 Jul 7;7(1):4914. doi: 10.1038/s41598-017-04895-z.)  
 
“The association of SBP with various TLR2 genotypes is somewhat controversial in the 
published literature. In the studies of Nischalke et al. [10] and Lutz et al. (Dig Liver Dis. 
2016 Jan;48(1):62-8. doi: 10.1016/j.dld.2015.09.011.) TLR2 -16934 TT genotype but not 
TLR2 R753Q and P631H mutations [10] were associated with SBP.” 
 
Regarding BT (Page 18 and 19):  “In patients with decompensated cirrhosis there was an 
increased translocation of bacterial DNA fragments into ascitic fluid in the presence of 
the NOD2 risk variant p.G908R (Harputluoglu MM. et al. Dig Dis Sci. 2016 
Jun;61(6):1545-52. doi: 10.1007/s10620-015-4024-y.). Moreover increased transition of 
pathologic BT to culture-positive SBP were reported in the case of the same NOD2 
variant.” (Bruns T, et al. Dig Dis Sci. 2016 Jul;61(7):2142-4 doi: 10.1007/s10620-016-4151-
0. Epub 2016 Apr 6. PubMed PMID: 27052012 and Bruns T, et al. Liver Int. 2016 
Aug;36(8):1133-42. doi: 10.1111/liv.13095.) 
 
The association of TLR4 with infections in cirrhosis (published in AP&T) has been cited in 
the original version of the manuscript  (Page 17) as follows: “In patients with advanced 
cirrhosis the TLR4 (D299G, rs4986790) variant was recognized to increase overall BI rates in 
a single retrospective study (n=111). [22]” 
 
Comment 5: “The multivariate analysis of risk factors for infection is missing. I would 
suggest a multivariate model including MELD and the presence of ascites (well known 
factors) and a step wise forward inclusion to identify further factors.” 
 
The rational why we did not show the results of multivariate analysis in the original version of 
the manuscript were the followings:  
(1) None of the examined PRR genotypes (individually or in any combination) were 
associated with the risk of non-SBP type bacterial infections. Thus, there was no need to 
adjust the results with relevant clinical factors in the multivariate analysis and evaluate 
whether they are independent risk factor of bacterial infections.  
(2) Previously we confirmed and reported in our patient cohort (Foldi I, Liver Int. 
2017 Jul;37(7):1023-1031. doi: 10.1111/liv.13368.) that advanced disease stage (depicted 
either by Child-Pugh stage, presence of ascites or decompensated clinical stage) was 
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8 
associated with risk of bacterial infection development using multivariate Cox-regression 
analysis and the backward elimination  procedure. 
(3) Instead, we would like to emphasize, that the history of a prior bacterial infection 
and an advanced disease stage had similar impacts on the infectious risk. Prior history of a 
bacterial infectious episode significantly increased the probability of the development of a 
subsequent bacterial infection, regardless of disease severity. To summarize these results, KM 
curves were constructed (Figure 3). 
 
We accept the suggestion of Reviewer 1 that it would be important to present which clinical 
factors are independent risk factors of bacterial infections. According to this request of the 
reviewer, we added this information to the Section – Results (Page 13): 
 
“Multivariate analysis  
Multivariate Cox-regression analysis and the forward inclusion procedure, taking all 
significant clinical co-variates of univariate analysis into account (see in Table 3), 
indicated that presence of ascites (HR [95%CI]: 1.71 [1.08-2.7], higher MELD score 
(1.08 [1.02-1.15]) and prior BI episode (2.02 [1.3-3.14]) were independently associated 
with the risk of a non-SBP type BI development during follow-up.” 
 
 
Variables in the Equation 
 β SE Wald df p- 
value 
Hazard  
Ratio 
95% CI 
Lower Upper 
Step 1 MELD score 0.115 0.028 17.379 1 <0.001 1.122 1.063 1.185 
Step 2 MELD score 0.100 0.028 12.771 1 <0.001 1.105 1.046 1.168 
Prior BI 0.706 0.225 9.895 1 0.002 2.027 1.305 3.148 
Step 3 MELD score 0.081 0.030 7.143 1 0.008 1.084 1.022 1.150 
Ascites 0.536 0.233 5.300 1 0.021 1.709 1.083 2.698 
Prior BI 0.704 0.225 9.840 1 0.002 2.023 1.303 3.141 
 
 
Minor points 
 
Comment 1: “Abstract: Please check spaces before parenthesis in the abstract section.”  
 
We inserted the missing spaces if needed. 
 
Comment 2: “Abstract: Please indicate whether the SBP frequencies are Kaplan-Meier 
estimates. If yes, please give standard errors.” 
 
We agree, that reporting standard errors (SE) along KM estimates is more informative. We 
amended our reporting of KM estimates in the abstract, Table 3 and in the manuscript body as 
well and included SEs.  
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9 
Comment 3: “Abstract: Please indicate the number of patients with ascites.” 
 
Eighty-eight patients had ascites at inclusion; we added it to the abstract. 
 
Comment 4: “Methods: Please indicate why genotyping was not performed in 55 patients - 
what does unavailable mean? May this introduce a bias?” 
 
We agree with the Reviewer 1 that this might introduce some bias. However, we had no 
possibility to organize our study otherwise.  
 As we stated in the Section of Patients and Methods – Study design, present study 
population was recruited consecutively between May 1, 2006 and December 31, 2010. At the 
time of inclusion we collected sera and whole-blood samples. Genomic DNA was extracted 
from whole-blood samples immediately and frozen -70 until testing.  
 Hungarian ethic legislations are rigorous, particularly in case of genetic studies and 
they went through substantial changes after 2010. First, they did not make possible to get a 
general permission for genetic analysis (testing certain gene variants in single study as a start 
and use DNA remnants for further different studies thereafter). Preservation of patients’ 
genomic DNA is possible after a single study but resubmission and authorization is obligatory 
for every further study. As to see patients or his or her legal surrogates and inform them about 
nature of the new genetic study and to sign a new informed consent form. Additionally in 
2011, National Scientific and Research Ethics Committee introduced a new legislation as 
well. In case of genetic studies permission of Regional and Institution Research Ethics 
Committee were not sufficient anymore even if it was a monocentric study. Since then, dual 
authorisation is required both from regional and national committees. In 2005, we got 
permission from regional committee for testing of MPO-463G/A polymorphism. 
Unfortunately, these results were never published due to lack of any association with either 
bacterial infections or progressive disease course. The idea of testing functional variants of 
PRR only came up after first publications in this field (Appenrodt B, et al. Hepatology. 2010 
Apr;51(4):1327-33. doi: 10.1002/hep.23440. and Nischalke HD, et al. J Hepatol. 2011 
Nov;55(5):1010-6. doi: 10.1016/j.jhep.2011.02.022.). Thereafter we had to resubmit the 
protocol of present genetic study in 2011 and also see each patient or legal surrogate after had 
getting ethical permissions (at the end of 2011 by regional and at the beginning of 2012 by 
national committees). Despite our efforts, it was not possible in case of above-mentioned 55 
patients. 
 Clinical characteristics of these patients however, did not differ from the tested cohort. 
Furthermore, the follow-up time was also similar between the tested and non-tested patient 
groups. We hope that these data are convincing for the Reviewer 1, and that the missing 
13.6% of the total cohort might not introduce substantial bias.  
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 Outpatients  Acute Decompensation  
 not missing 
(n=243) 
missing 
(n=34) 
p-value not missing 
(n=106) 
missing 
(n=21) 
p-value 
Age 
56 
(50-63) 
54 
(46-66) 
0.661 58 
(51-64) 
54 
(48-66) 
0.520 
Child-Pugh 
score 
6 
(5-8) 
7 
(5-8) 
0.403 9 
(7-11) 
10 
(8-11) 
0.173 
MELD score 
11 
(8-14) 
12 
(9-15) 
0.290 17 
(13-22) 
20 
(15-22) 
0.231 
Creatinine 
µmol/L 
67 
(54-84) 
63 
(54-71) 
0.282 77 
(59-130) 
99 
(69-187) 
0.217 
Bilirubin 
µmol/L 
26 
(16-41) 
31 
(16-53) 
0.298 55 
(27-109) 
63 
(34-99) 
0.534 
INR 
1.17 
(1.09-1.32) 
1.25 
(1.15-1.34) 
0.082 1.42 
(1.2-1.74) 
1.54 
(1.34-1.73) 
0.231 
Albumin 
g/L 
38 
(33-42) 
38 
(32-41) 
0.995 28 
(24-32) 
24 
(22-33) 
0.174 
Follow-up 
time 
988 
(366-1825) 
703 
(85-1774) 
0.107 147 
(17-732) 
63 
(9-297) 
0.069 
Gender 
(female) 
127 
(52.3%) 
13 
(38.2%) 
0.125 35 
(33%) 
11 
(52.4%) 
0.092 
Etiology 
(alcohol) 
152 
(62.6%) 
24 
(70.6%) 
0.362 90 
(84.9%) 
18 
(85.7%) 
0.924 
Child-
Pugh 
A 
137 
(56.4%) 
18 
(52.9%) 
0.771 14 
(13.2%) 
2 
(9.5%) 
0.422 
B 
92 
(37.9%) 
13 
(38.2%) 
43 
(40.6%) 
6 
(28.6%) 
C 
14 
(5.8%) 
3 
(8.8%) 
49 
(46.2%) 
13 
(61.9%) 
Ascites 
88 
(36.2%) 
10 
(29.4%) 
0.437 80 
(75.5%) 
18 
(85.7%) 
0.307 
 
 
Comment 5: “Methods: Why were clinical data determined by review of medical records? 
This was a prospective study with a designed CRF? Please clarify, which data were assessed 
retrospectively.” 
 
At enrollment a structured interview was used for capturing clinical data about the period 
prior to the observational follow-up study (retrospective data collection by an in-depth review 
of patients’ medical records), since mean disease duration from diagnosis of cirrhosis was 3.9 
± 4.2 years among patients at the time of the inclusion. These were the followings: age at 
diagnosis, etiology, presence of hepatocellular carcinoma, esophageal varices, extrahepatic 
co-morbidities, history of previous AD episode(s), and cirrhosis-related medication were 
retrospectively analyzed for the period prior to the observational follow-up study. At 
enrollment, laboratory parameters, disease severity – assessed by liver-oriented scores (Child-
Pugh and MELD) and clinical stage of the disease (compensated/ decompensated) – was 
determined.  
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All data collection after the inclusion was performed prospectively. Structured interview was 
used for capturing data again. Collected data were the follows: date and type of bacterial 
infection warranting hospital admission and the development of disease specific 
complications (ascites, hepatic encephalopathy or variceal bleeding). 
 
Structured interview either at enrollment or later in the study ensured that data collection and 
data entering into database would be unified among attending physicians (senior hepatologist, 
n=3 and junior gastroenterologist, n=2) all the time, during regular and extraordinary 
outpatient follow-up visits and inpatient stays in a prospective manner. In Hungary, a regular 
outpatient follow-up visit is usually scheduled for every 3 months at a specialized 
gastroenterology center for patients with decompensated cirrhosis (a follow-up between 1-3 
months may be scheduled if dictated by disease severity or the presence of certain disease 
specific complications) and for up to 6 months for patients with cirrhosis but without a prior 
episode of AD.  
Collected data were transferred and stored in a database. At the end of the study period on 
December 31, 2013, all clinical data was extracted for further analysis.  
 
Comment 6: “Methods: Microbial analysis in SBP was performed in only 11 cases. A lack of 
bacteriological testing may also explain the low frequency of bacteriemia in follow up.” 
 
We mentioned it as a drawback of present study in the Section – Discussion (Page 17). 
“Present study did not allow for an in-depth analysis of the association of PRR variants with 
different types of SBP (culture-negative, culture-positive or bacterascites), which is a 
drawback.  Since there was twenty incident cases of SBP during follow-up and only half of 
them was cultured.” 
 
Comment 7: “Methods: How was censoring performed in KM-analysis? Were patients right-
censored at death? How many patients were transplanted? Please indicate censored patients 
in the KM blots. Please indicate the patients at risk in Figure 2B.” 
 
In KM-analysis for the development of non-SBP BI, SBP and decompensation event, 
censoring of patients (right-censoring) was performed in case of transplantation, death or loss 
of follow-up, whilst in survival analysis in case of transplantation or loss of follow-up. We 
added this information to the Section of Patients and Methods – Statistical analysis (Page 11).  
 
During the study period, 4 patients were transplanted in this cohort that corresponds to the 
expected annual rate of transplantation/ inhabitants in Hungary: around fifty cases/year for 10 
million-population between 2006 and 2013. 200,000 inhabitants belong to our university 
hospital and median follow-up lasted 1128 days (IQR: 469-1825) in the present study. 
 
We indicated censored patients in the KM plots and patients at risk in Figure 2B. 
 
Comment Awkward Phrases/Language:  
 
We corrected the indicated language items and in accordance with the request of the 
Associate Editor a professional English editing was also performed and highlighted in the 
text. 
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- Introduction: “can be like to” - can be linked to 
- Introduction: “namely advent of decompensation events” – such as development of 
decompensation events 
- Methods: “clinical stage of the diseases” – clinical stage of the disease 
- Methods: “genetic DNA” (it is genomic) – genomic DNA  
- Results: “Mortality occurred in 82 subjects” –  liver-related death occurred in 
- Page 14 and others: Please stick with nomenclature of human genes and symbols (italic, 
large capitals) consistently. – We unified the nomenclature in the manuscript  
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13 
Reviewer 2 
 
Comment 1: “Did the authors analyse the intake of antibiotics, if yes how did they analyse 
“this influence”. “Some patients with liver cirrhosis take rifaximin, an antibiotic treatment 
for prophylaxis for hepatic encephalopathy. These patients have to analysed separately.” 
 
In the present cohort, 23 patients received norfloxacin, while 14 rifaximin at enrolment as a 
secondary prophylaxis of SBP or hepatic encephalopathy, respectively. The indication for 
rifaximin was the insufficient response to lactulose and was administered as an add-on-
therapy to lactulose. None of the examined NOD2, TLR2 and TLR4 gene variants was 
different between patients with or without receiving secondary antibiotic prophylaxis. We 
completed the Section – Results, Genotype distribution of various functional polymorphisms 
of PRRs in cirrhosis (Page 11-12) and Table 1 with these data.  
 
 “Co-medications at enrolment comprising use of proton pump inhibitor (PPI), non-
selective beta blocker (NSSB) and secondary antibiotic prophylaxis either norfloxacin 
for prevention of SBP or rifaximin for prevention of HE were also not different among 
patients with genetic variants of NOD2, TLR2 and TLR4 and with wilde-type (Table 1).”  
 
 
 
 
Total NOD2 polymorphismb 
TLR2 16934T>A 
polymorphism 
rs4696480 
TLR4 D299G A>G  
polymorphism 
rs4986790× 
 
 
(N=243)
* 
Wild 
type  
(N=204) 
Risk 
allele 
(N=37) 
P-
value 
TT 
(N=64) 
TA 
(N=104) 
AA 
(N=74) 
P-
value 
AA 
(N=225) 
AG 
(N=17) 
P-value 
Secondary antibiotic 
prophylaxis 
 
          
Norfloxacin for 
prevention of SBP 
 
 
9.5% 
(23) 
8.8% 
(18) 
13.5% 
(5) 
0.372 
6.3% 
(4) 
13.5% 
(14) 
6.8% 
(5) 
0.189 
9.3% 
(21) 
11.8% 
(2) 
 
0.742 
Rifaximin for 
prevention of HE 
5.8% 
(14) 
5.4% 
(11) 
8.1% 
(3) 
0.457 
7.8% 
(5) 
3.8% 
(4) 
6.8% 
(5) 
0.515 
5.8% 
(13) 
5.9% 
(1) 
0.986 
 
 
We included secondary antibiotic prophylaxis as a clinical co-variate during exploring risk 
factors of non-spontaneous bacterial peritonitis type bacterial infections (non-SBP type BI) 
during the follow-up period (Table 3) such we did in the case of PPI and NSSB medication in 
the original version of the manuscript. Secondary antibiotic prophylaxis was not associated 
with an increased cumulative probability of non-SBP type of BI. We added these data to 
Table 3. 
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14 
Pertinent part of Table 3. Association of clinical factors with the development of non-
spontaneous bacterial peritonitis type bacterial infections. 
 
  
Non-SBP type BI development Univariate Cox regression 
  
n of  
subjects 
n of  
events 
CP of  
BI ± SE 
P- 
value* HR 95%CI 
P- 
value 
Total cohort 
 
243 85 49.6±4.1     
Secondary antibiotic prophylaxis        
Norfloxacin for  
prevention of SBP 
no 220 75 49.0±4.3 0.108 1.71 (0.88 - 3.31) 0.112 
yes 23 10 52.5±12.0     
Rifaximin for 
prevention of HE 
no 229 78 48.3±4.2 0.109 1.86 (0.86-4.04) 0.115 
yes 14 7 80.4±16.1     
 
Due to these findings we did not analyze further these small groups of patients separately. 
 
Comment 2 Part 1: “Patients with prior SBP take antibiotic prophylaxis. Did these patients 
developed also Non-SBP bacterial infections?” 
 
The requested data are presented in Table 3. Cumulative probability of a non-SBP type BI 
was similar between patients with or without a prior history of SBP. This finding might 
support the idea that the mechanisms of the development of these infections (SBP vs. non-
SBP type BI) are different. In SBP, it is mainly related to intestinal bacterial translocation 
(BT), however it is not a major contributor in the development of non-SBP type BIs.  
 
 
  
Non-SBP type BI development Univariate Cox regression 
  
n of  
subjects 
n of  
events 
CP of  
BI ± SE 
P- 
value* HR 95%CI 
P- 
value 
Total cohort 
 
243 85 49.6±4.1     
Prior SBP absent 220 75 49.0±4.3 0.108 1.71 (0.88 - 3.31) 0.112 
present 23 10 52.5±12.0     
 
 
The Comment 2 Part 2 and Comment 3 are related to each other therefore we would like to 
answer for them simultaneously. 
 
Comment 2 Part 2: “We are learning more and more about the two sides of ßeta-blockers. 
We have understood a negative influence in patients with decompensated cirrhosis like 
patients with refractory ascites or with spontaneous bacterial peritonitis. On the other side, 
we know protective influences of ßeta-blockers in the cascade of bacterial translocation. The 
authors include patients with ß-blockers. Could the authors give us more details about the 
cirrhosis grade and the intake of ß-blockers. The patients should be analysed separately 
(groups like: no NSBB, NSBB and good liver function, NSBB and bad liver function)” 
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15 
In the present cohort, NSBB use was significantly higher in the advanced diseases stage: 58% 
(51/88) vs. 41.9% (65/155) in patients with or without ascites (p=0.016). Corresponding data 
according to Child-Pugh stage were the followings: 71.4% (10/14) for Child C, 51.1% (47/92) 
for Child B and 43.1% (59/137) for Child A (p for trend= 0.039).  
 
In Table 3 in the original version of the manuscript, we reported that the CI of the 
development of non-SBP type BI did not differ between NSBB users and non-users. 
According to the suggestion of Reviewer 2 we evaluated this association further taking into 
account disease severity (presence or absence of ascites). Likewise, there was also no 
association between NSBB use and the development of BI in KM analysis. In the subgroup of 
patients without ascites, the cumulative probability (±SE) of non-SBP type BI was 49.1±7.4% 
in NSBB users, while 36.2±6.8% in non-users (pLogRank=0.122). Corresponding data in the 
subgroup of patients with ascites were 68.2±9.1% and 62.2±9.7% (pLogRank=0.787).  
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Comment 3: “The authors should analyse separately patients with and without NSBB and 
with and without PPI” 
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17 
The requested data are summarized in the above series of KM curves; however, these are only 
provided for the Reviewer 2. Interpretation of data about the effect of various drugs on long-
term disease outcomes raises some problems. Distinctly to secondary prophylaxis of SBP or 
hepatic encephalopathy in case of certain drugs, like PPIs, episodic use is expected at least in 
some of the cases. In case of NSSB, though continuous long-term use is highly expected once 
it started. Drug discontinuation – either temporarily or permanently – however should also be 
required when contraindications arise. Thus, not only the administration of the drug used at 
inclusion but also their exact duration should be considered. This approach to the assessment 
of various medications was beyond scope of the present study. 
 
In expert opinion (Beta-blockers in decompensated cirrhosis, Academic Debates – AASLD 
2017, 20th of October), evaluating the effect of co-medications on various outcomes (e.g. 
bacterial infections, decompensation events or mortality) is somewhat questionable and 
results are hard to interpret in studies that were designed to evaluate other factors than co-
medications. 
 
Comment 4: “The authors should specify the origin of SBP (nosocomial versus outpatient)” 
 
All the bacterial infections comprising SBP were community acquired. In the Section – 
Patients and Methods, Study design (Page 7) we stated the followings:“Outpatients at 
inclusion (n=243) were enrolled into an observational follow-up study where the attending 
gastroenterologist registered the date and type of bacterial infection (BI) warranting hospital 
admission (diagnostic criteria are summarized in Supplementary Material) and the 
development of disease specific complications (ascites, hepatic encephalopathy or variceal 
bleeding) during regular and extraordinary outpatient follow-up visits and inpatient stays in a 
prospective manner.” 
 
We added to the Section – Results, Risk factors of SBP(Page 14) that these episodes were 
community acquired. 
 
“Of the patients with ascites 22.7% (20/88) developed community acquired SBP during the 
follow-up period.” 
 
Comment 5: “Did the authors analyse the survival rates in patients with genetic variants of 
NOD2 and TLR2/4 and with wildtype? 
 
We provided these requested data in the Section – Results (Page 15) and Supplementary 
Figure 3. Unfortunately, during the PDF generation of the original manuscript, it did not 
cover the Supplementary material. Probably it was not available for the Reviewer 2 during the 
review process. Now we presented the survival curves in patients with genetic variants of 
NOD2 and TLR2/4 and with wild type below. 
 
“Functional polymorphisms of PRR genes and survival 
In the total cohort, liver-related death occurred in 82 (33.7%) subjects. Median time to 
mortality was 660 (304-977) days. Kaplan-Meier survival analysis demonstrated a 
significantly worse survival in patients with advanced disease according to presence of ascites 
(PLogRank<0.001), Child-Pugh stage B/C (PLogRank<0.001), or decompensated clinical stage 
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18 
(PLogRank=0.033) and prior BI episode (PLogRank=0.050). Neither NOD2 risk variants (PLogRank= 
0.785) nor TLR2 (-16934A>T) and TLR4 (D299G) polymorphisms (PLogRank= 0.682 and 
0.732) were associated with overall survival (Supplementary Figure 3).” 
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19 
Supplementary Figure 3. Kaplan–Meier analysis of survival with respect to the presence of NOD2 risk alleles (L1007fsinsC -/C, R702W C>T or G908R 
G>C) (A) and TLR2 (T-16934A) (B) or TLR4 (D299G) (C) polymorphisms in outpatients. 
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20 
Comment 6: “Could the authors please comment in more detail the different types of Non-
SBP bacterial infection and their association to the genetic variants of NOD2, TLR2 and 
TLR4? For example, is there an association between genetic variants and the risk of e.g. 
pneumonia or urinary tract infection?” 
 
In our study we divided BIs into two groups: SBP and non-SBP type BIs. The rational of this 
categorization based on the established concept that the mechanisms of the development of 
these two groups of infections are different. Intestinal BT is an important mechanism in the 
development of SBP. And though systemic infections beyond SBP might also be related to 
BT (e.g. GNB caused skin infections – enteric bacteria reach the systemic circulation, cause 
bacteremia and seed the tissues of the extremities [Chang CM, et al. Infection. 2008 Aug;36(4):328-
34. doi: 10.1007/s15010-008-7272-3.]) but it is not the major contributor in the development of 
these infections. In the present cohort evaluating first BI episodes after enrolment, eighty-five 
(35%) of the included outpatients encountered a non-SBP type BI episode. The incident cases 
were assigned into seven subgroups according to the location of the infection. (Summarized in 
Section of Results – Page 12). We fully agree with this suggestion of the Reviewer 2, however 
taking into account the low number of cases in seven various location subgroups and the 
occurrence of different PRR variants (16.4%, 24.8% and 6.6% for any NOD2 variants, TT 
genotype of TLR2 [16934T>A] and AG genotype of TLR4 D299G, respectively) did not make 
it possible to address this issue adequately, due to lack of statistical power. This is inevitably a 
drawback of our study. In the revised version of the manuscript we mentioned this limitation 
(Section – Discussion [Page 18]).  
 
“The limited number of incident cases in the seven different location subgroups did not 
make possible the more subtle assessment of the potential role of PRR variants in the 
development of certain type of infection that is an inevitable drawback of the present 
cohort.” 
 
 
We hope that the quality of the revised version of the manuscript improved significantly and 
hope that this new version will reach the high standards of Liver International  
 
Thank you very much for your kind helps and appreciation, 
Sincerely yours, 
 
 
 
Maria Papp, MD, PhD  
Department of Internal Medicine 
Division of Gastroenterology         
Faculty of Medicine 
University of Debrecen            
Nagyerdei krt 98, Debrecen           
H-4032 Hungary            
Phone: +36-52-255-196          
E-mail: papp.maria@med.unideb.hu 
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ABSTRACT  
Background&Aims: Pattern recognition receptors (PRRs) have a key role in 
the innate host defense. Functional polymorphisms of various PRRs have 
been established to contribute to an increased susceptibility to spontaneous 
bacterial peritonitis (SBP). Their role in the development of cirrhosis-
associated bacterial infections (BI), beyond SBP or progressive disease 
course related to pathological bacterial translocation (BT) remains unknown. 
Methods: 349 patients with cirrhosis were genotyped for common NOD2 
(R702W, G908R and L1007PfsinsC), TLR2 (-16934T>A), and TLR4 (D299G) 
gene variants. Incidence of BIs, decompensating events (ascites, variceal 
bleeding and hepatic encephalopathy) and liver-related death were assessed 
in a 5-year follow-up observational study. Pathological BT was assessed 
based on the presence of anti-microbial antibodies or lipopolysaccharide-
binding protein (LBP) level. Results: In patients with ascites (n=88) only 
NOD2 gene variants were associated with an increased cumulative probability 
of SBP compared to wild-type (76.9%±19.9% vs. 30.9%±6.9%, 
PLogRank=0.047). Neither individual polymorphisms, nor combined PRR genetic 
profiles were associated with the risk of non-SBP type BI. Advanced disease 
stage (HR,[95%CI]: 2.11 [1.38-3.25]) and prior history of a BI episode (HR: 
2.42 [1.58-3.72]) were the major clinical risk factors of a subsequent BI. The 
risk of a non-SBP type BI in patients with advanced disease and a prior BI 
was even higher (HR: 4.74 [2.68-8.39]). The frequency of anti-microbial 
antibodies and LBP levels did not differ between various PRR genotypes. 
Correspondingly, PRR genetic profile was not able to predict the long-term 
disease course. Conclusions: In cirrhosis, functional polymorphisms of PRRs 
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did not improve the identification of patients with high risk of BI beyond SBP 
or progressive diseases course. 
 
Word count for abstract: 250 
Key words: pattern recognition receptors, genetic polymorphisms, cirrhosis, 
bacterial infection, complications, mortality 
 
Key Points 
• In this 5-year follow-up study, we evaluated the role of functional 
polymorphisms of various PRRs (NOD2, TLR2, and TLR4) in the 
development of bacterial infections, clinical decompensation and 
mortality in patients with cirrhosis. 
• We confirmed that NOD2 va iants were risk factors of SBP in patients 
with ascites.  
• Clinical factors (advanced disease and history of a bacterial infection)  
were major determinants of non-SBP type bacterial infections. 
• We found no association between PRR gene variants and serologic 
markers of pathological bacterial translocation. Concordantly, patients 
with PRR gene variants did not have an increased risk for clinical 
decompensation or mortality. 
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INTRODUCTION 
Pathological bacterial translocation (BT) is a characteristic feature of cirrhosis, 
mainly in the advanced disease stage, and it plays an essential role in the 
pathogenesis and the development of various complications of the disease. 
The most evidenced clinical consequence of BT is the spontaneous bacterial 
peritonitis (SBP) and bacteremia. [1] Systemic infections beyond SBP might 
also be related to BT. Even in the absence of an overt infection, sustained 
entry of various bacterial products into the hepato-splanchnic and systemic 
circulation can also have a deleterious effect by inducing an enhanced pro-
inflammatory response. Failure to control invading bacteria and/or their 
products, together with an increased host susceptibility to infection, may result 
in the damage of the remote organ. [2] Development of consequential organ 
failure(s) is a major determinant of mortality in this patient population. [3] 
 Accurate identification and risk stratification of BT can efficiently aid the 
preventive strategies against bacterial infections and other complications of 
cirrhosis. Direct data on culturable BT to mesenteric lymph nodes and 
upstream compartments is not available in humans. Recently, various 
serologic markers (e.g. lipopolysaccharide binding protein [LBP], [4] bacterial 
DNA [5] or IgA type anti-microbial antibodies [6,7]) have been proposed to 
reflect sustained gut microbial exposure. Additionally, susceptibility genes for 
pathological BT have also been revealed. Functional polymorphisms of 
pattern recognition receptors (PRRs) alter the detection and clearance of 
bacterial pathogens, thus influencing the innate host defence mechanisms. 
Single nucleotide polymorphisms (SNPs) in the promoter and the encoding 
regions of nucleotide-binding oligomerization domain (NOD) [8,9] or toll-like 
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receptors (TLR) [10,11] were reported to increase the risk of SBP. However, 
their comprehensive evaluation regarding non-SBP type bacterial infections, 
or various other aspects of progressive disease course in cirrhosis has not 
been fully elucidated so far.  
 In the present study, we aimed to investigate the clinical importance of 
functional polymorphisms of various PRRs in a large cohort of patients with 
cirrhosis. In a 5-year follow-up observational study, we evaluated whether 
certain genetic variants of NOD2, TLR2 and TLR4 (1) constitute a risk for the 
development of SBP or non-SBP type bacterial infections; (2) can be linked to 
the established serologic markers of bacterial translocation; (3) constitute a 
risk for the progressive disease course, such as development of 
decompensation events (ascites formation, hepatic encephalopathy or 
variceal bleeding), or liver-related mortality.  
 
PATIENTS AND METHODS  
Study design  
We performed a cohort study among adult patients with an established 
diagnosis of cirrhosis of different etiologies, in a tertiary care referral center of 
Hungary (Division of Gastroenterology Department of Internal Medicine, 
Clinical Center, University of Debrecen). The present study population is a 
part of our entire patient cohort comprising a total of 404 patients with 
cirrhosis who were recruited consecutively between May 1, 2006 and 
December 31, 2010 from the outpatient clinic during regular, or extraordinary 
follow-up visits, and also from the inpatient ward, when hospitalized with an 
acute decompensation (AD) episode [12,13]. For the present study, blood 
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samples from 349 patients were available (243 outpatients and 106 
hospitalized subjects due to an AD episode) (Figure 1). Acute 
decompensation was defined by the acute development of large ascites 
(grade II/III) [14], acute hepatic encephalopathy [15], acute variceal bleeding 
[16] and/or the presence of systemic bacterial infection.  
 Clinical characteristics of patients at inclusion are presented in Table 1. 
Mean disease duration from diagnosis of cirrhosis was 3.9 ± 4.2 years among 
patients at the time of the inclusion. Blood samples, routine laboratory data 
and a detailed clinical phenotype were captured at inclusion. Clinical data was 
determined by an in-depth review of patients’ medical records using a 
structured interview. Medical records that documented age at diagnosis, 
etiology, presence of hepatocellular carcinoma, esophageal varices, 
extrahepatic co-morbidities, history of previous AD episode(s), and cirrhosis-
related medication were retrospectively analyzed for the period prior to the 
observational follow-up study. At enrollment, disease severity – assessed by 
liver-oriented scores (Child-Pugh and MELD) and clinical stage of the disease 
(compensated/ decompensated) – was always determined. 
 Outpatients at inclusion (n=243) were enrolled into an observational 
follow-up study where the attending gastroenterologist registered the date and 
type of bacterial infection (BI) warranting hospital admission (diagnostic 
criteria are summarized in Supplementary Material) and the development of 
disease specific complications (ascites, hepatic encephalopathy or variceal 
bleeding) during regular, and extraordinary, outpatient follow-up visits and 
inpatient stays in a prospective manner. In Hungary, a regular outpatient 
follow-up visit is usually scheduled for every 3 months at a specialized 
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gastroenterology center for patients with decompensated cirrhosis (a follow-
up between 1-3 months may be scheduled if dictated by disease severity or 
the presence of certain disease specific complications) and for up to 6 months 
for patients with cirrhosis but without a prior episode of AD. Follow-up period 
lasted for 5 years, or until death/loss of follow-up. Eighty-two (34%) patients 
died during follow-up, median time to death was 660 days (IQR: 304-977). In 
the 181 patients without death occurring, median follow-up lasted 1128 days 
(IQR: 469-1825). Collected data were transferred and stored in a database. At 
the end of the study period on December 31, 2013, all clinical data was 
extracted for further analysis.  
 
Gene analysis of NOD2, TLR2 and TLR4 
Genomic DNA was extracted from whole-blood samples using the Gentra 
Puregene Blood Kit (Qiagen; Hilden, Germany) following the manufacturer’s 
protocol. Three alleles of the NOD2 gene variants rs2066844, (p.R702W:, 
NM_022162.2:c.2104C>T), rs2066845 (p.G908R; NM_022162.2:c.2722G>C), 
and rs2066847 (L1007Pfs; NM_022162.2:c.3019dupC) were genotyped using 
hybridization probes on fluorescence resonance energy transfer (FRET) on a 
LightCycler 480 (Roche) real-time PCR system, according to Ferreiros-Vidal 
et al [17]. Gene variant of TLR2 gene rs4696480 (NM_003264.4:c.-
148+1614T>A) was also genotyped using oligonucleotides according to Oh et 
al. [18]. The gene variant of TLR4 gene rs4986790 (p.D299G; 
NM_138554.4:c.896A>G) was genotyped using self-designed amplification 
oligos (TLR4-D299G F: CATCGTTTGGTTCTGGGAG and TLR4-D299G R: 
TTTACCCTTTCAATAGTCACACTCA), while FRET oligonucleotides were 
Page 28 of 78Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9 
similar to Hamann et al. (TLR4-D299G SENS: 
CTACTACCTCGATGGTATTATTGACTTATT-6FAM, TLR4-D299G ANCH: 
Cy5.5 -AATTGTTTGACAAATGTTTCTTCATTTTCC-3’phosph) [19]. 
Representative melting curve genotyping results are shown in the 
Supplementary Figure 1. Genotyping was technically unsuccessful in two 
patient samples for NOD2 analysis, and in one sample for TLR2 and TLR4 
analysis. 
 
Serologic analysis 
Serum levels of total bilirubin, creatinine, and albumin, blood cell count and 
INR were determined by routine laboratory analysis. 
 Blood samples were obtained at enrollment from each patient and were 
frozen at -70°C until testing. All the serological assays were performed in a 
blinded fashion without prior knowledge of the patient’s clinical information. 
Commercially available sandwich enzyme-linked immunosorbent assays 
(ELISA) were used according to the manufacturer’s protocol to determine 
serologic markers of pathological BT, namely lipopolysaccharide-binding 
protein (LBP) (Hycult Biotechnology, Uden, Netherlands), endotoxin core IgA 
antibody (EndoCAb IgA) (Hycult Biotechnology, Uden, Netherlands) and anti-
OMP Plus IgA antibody (QUANTA Lite®, Inova Diagnostics, San Diego, CA). 
EndoCAb directs against a mixture of incomplete endotoxins of 4 different 
species (Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli 
and Klebsiella aerogenes), while anti-OMP Plus antibody does to a mixture of 
multiple bacterial proteins derived from two species of intestinal bacteria (one 
Gram-positive and one Gram-negative). Cut-off positivity was 195 AU/mL for 
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EndoCAb IgA, defined by our group previously [19] as a value exceeding the 
95th percentile level of the healthy control group, and 25 U for anti-OMP Plus 
IgA as recommended by the manufacturer.  
 
Ethical considerations 
The study protocol was approved by the Regional and Institutional Research 
Ethics Committee of University of Debrecen and by the National Scientific and 
Research Ethics Committee (DEOEC-RKEB/IKEB 5306-9/2011, 
3885/2012/EKU [60/PI/2012]). Each patient or legal surrogate was informed of 
the nature of the study and signed an informed consent form. 
 
Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous 
variables were summarized as means (standard deviation [SD]) or as 
medians (interquartile range [IQR, lowest 25%-highest 25%]) according to 
their homogeneity. Categorical variables were compared with Fisher’s exact 
test or χ
2 test with Yates correction, as appropriate. Continuous variables 
were compared with Mann-Whitney U test or Kruskal-Wallis H test with 
Dunn’s multiple comparison post hoc analysis. Allele frequencies of the 
respective SNPs were tested for deviations from the Hardy–Weinberg 
equilibrium and then compared for statistical differences with the Cochrane 
Armitage trend test (Helmholtz Center Munich, http://ihg.gsf.de/cgi-bin/hw/ 
hwa1.pl). Kaplan–Meier (KM) analysis was used to calculate the cumulative 
probability (CP) of adverse outcomes (development of non-SBP BI, SBP, 
decompensation event and mortality). Right censoring of patients was 
Page 30 of 78Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 11
performed in case of transplantation or loss of follow-up as appropriate. 
Differences in observed probabilities were assessed by the log-rank test. The 
association between categorical clinical variables, or different PRR 
genotypes, and adverse disease outcomes during follow-up was assessed by 
univariate Cox-regression analysis. Multivariate analyses were performed with 
a forward inclusion procedure and a likelihood ratio test to identify 
independent predictors. Binary logistic regression was used to assess the 
infection-related mortality at 28 and 90 days. Associations are given as a 
hazard ratio [HR] or odds ratio [OR] with 95% confidence intervals [CI]. For 
statistical analysis and graphical presentation, the SPSS 24.0 [SPSS, 
Chicago, IL], and GraphPad Prism 6 programs were used. A 2-sided 
probability value of <0.05 was considered statistically significant.  
 
RESULTS 
 
Genotype distribution of various functional polymorphisms of PRRs in 
cirrhosis  
Frequencies of various PRR genotypes in cirrhosis are summarized in Table 
2. None of the examined NOD2, TLR2 and TLR4 gene variants was different 
between outpatients and patients with AD. Further analysis of clinical and 
laboratory characteristics of outpatients revealed that age, gender, presence 
of a co-morbidity or HCC, etiology or severity of cirrhosis was not different 
across the various PRR genotype subgroups. Co-medications at enrolment 
comprising the use of proton pump inhibitor (PPI), non-selective beta blocker 
(NSSB) and secondary antibiotic prophylaxis either norfloxacin for prevention 
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of SBP or rifaximin for prevention of HE were also not different among 
patients with genetic variants of NOD2, TLR2 and TLR4 and with wilde-type 
(Table 1).  
 
Risk factors of non-SBP type BI  
Eighty-five (35.0%) of the included outpatients encountered a non-SBP type 
BI episode during the follow-up period. The median time to development of a 
first BI episode was 581 (207-803) days. Urinary tract infection was the most 
commonly diagnosed BI, and accounted for 43.5% (n=37) of the events. 
Other sites of BI were as follows: pneumonia (18.8%), erysipelas (10.6%), 
acute bronchitis (5.9%), cholangitis (3.5%), bacteremia (3.5%), gastroenteritis 
(1.2%) and unidentified in 9 (10.6%) cases. 2.4% of the cases were multifocal. 
Microbiological analysis was performed in 35 (41.2%) cases. Bacteria were 
Gram-negative in 76.5% and Gram-positive in 23.5% of culture positive cases 
(n=17) (Supplementary Material).  
 
Functional polymorphisms of PRR genes  
Patients with any risk variants in NOD2, TLR2 or TLR4 genes did not have an 
increased cumulative probability of a non-SBP type BI episode during follow-
up (Figure 2A), not even when stratifying according to presence of ascites 
(Figure 2B). Patients carrying both a TLR2 variant and at least one NOD2 
risk variant (n=10) had also a similar rate of non-SBP type BI, than patients 
not carrying both variants (PLogRank=0.397). There was no rationale for testing 
the potential effect of the TLR4 and NOD2 variant combination. Only one 
patient carried both variant genotypes. 
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 The presence or absence of a NOD2, TLR2 or TLR4 variants did not 
affect the type of pathogen causing BI (Gram-negative or –positive), or the 
location of BI. 
 Furthermore, these PRR gene variants were not associated with the 
risk of mortality during a subsequent bacterial infection (Supplementary 
Table 2).  
  
Clinical co-variates 
Of the clinical factors: co-morbidity, PPI use, prior history of a BI episode and 
advanced disease stage were all associated with an increased cumulative 
probability of non-SBP type BI episodes during the follow-up period (Table 3).  
Of the patients with a prior history of BI, 66.5%±6.3% (standard error) 
developed another BI episode, compared to 39.7%±5.1 % of those with no 
such history (PLogRank:<0.001). Regarding advanced disease stage, similar 
results were found if advanced disease stage was depicted either by the 
presence of ascites (65.2%±6.6% vs. 42.0%±5.1%, PLogRank:<0.001), Child-
Pugh stage B/C (68%±6.1% vs. 38.1%±5.2%, PLogRank:<0.001) or by 
decompensated clinical stage (58.8%±5.7% vs. 40.8%±5.8%, PLogRank=0.01).  
The combination of these two relevant clinical factors revealed important 
findings. First, prior history of a BI episode significantly increased the 
probability of the subsequent development of another BI event, regardless of 
disease severity. Furthermore, a prior history of a BI without ascites was 
associated with the same cumulative probability of a BI occurring, as the 
presence of ascites without prior history of a BI (57.3%±8.7% and 
51.0%±9.9%, respectively). The combined presence of both clinical risk 
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factors resulted in an even higher cumulative probability of BI (80.3%±7.7%) 
(Figure 3 and Table 3). 
 
Multivariate analysis  
Multivariate Cox-regression analysis and the forward inclusion procedure, 
taking all significant clinical co-variates of univariate analysis into account, 
indicated that presence of ascites (HR [95%CI]: 1.71 [1.08-2.7], higher MELD 
score (1.08 [1.02-1.15]) and prior BI episode (2.02 [1.3-3.14]) were 
independently associated with the risk of a non-SBP type BI development 
during follow-up. 
 
Risk factors of SBP  
Of the patients with ascites 22.7% (20/88) developed community acquired 
SBP during the follow-up period. Of the cases with microbiological 
investigation, 36.4% (4/11) was culture-positive SBP, while 63.6% (7/11) was 
culture negative. Bacteria were Gram-negative in 75% and Gram-positive in 
25% of culture positive cases (Supplementary Material). The median time to 
the development of SBP was 340 (126-662) days. The presence of NOD2 risk 
allele variants, but not of TLR2 and TLR4 variants, were associated with an 
increased cumulative probability of SBP (Figure 4). Of the patients with any 
NOD2 risk variants 76.9%±19.9% developed SBP, compared to 30.9%±6.9% 
of those with NOD2 wild type (PLogRank=0.047). Patients with or without any 
NOD2 risk allele variants had similar MELD scores (median [IQR]: 14 [9-16] 
vs. 13 [10-15], respectively, P=0.874). Prior SBP episode was also associated 
with the risk of SBP development (PLogRank=0.048). 
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Association of functional polymorphisms of PRR genes with serologic 
markers of BT 
Serum level of LBP and frequencies of IgA type antibodies directed against 
various gut microbial components (anti-OMP Plus and EndoCab) were not 
different according to the examined PRR genotypes (Table 4). 
 
Functional polymorphisms of PRR genes and development of 
decompensation events 
Of the patients with a compensated clinical stage at enrolment 31.4% 
(38/121) developed any type of decompensation event (ascites, variceal 
bleeding or hepatic encephalopathy). The median time to the development of 
a first decompensation was 540 (140-913) days. Neither NOD2 risk variants 
(PLogRank=0.681) nor TLR2 and TLR4 polymorphisms (PLogRank= 0.068 and 
0.249) were risk factors of clinical decompensation (Supplementary Figure 
2). 
 
Functional polymorphisms of PRR genes and survival 
In the total cohort, liver-related death occurred in 82 (33.7%) subjects. Median 
time to mortality was 660 (304-977) days. Kaplan-Meier survival analysis 
demonstrated a significantly worse survival in patients with advanced disease 
according to presence of ascites (PLogRank<0.001), Child-Pugh stage B/C 
(PLogRank<0.001), or decompensated clinical stage (PLogRank=0.033) and prior 
BI episode (PLogRank=0.050). Neither NOD2 risk variants (PLogRank= 0.785) nor 
TLR2 and TLR4 polymorphisms (PLogRank= 0.682 and 0.732) were associated 
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with overall survival (Supplementary Figure 3). 
 
DISCUSSION 
 Bacterial infections beyond SBP have significant prognostic 
implications in patients with cirrhosis [1]. Thus, individual risk stratification for 
BI is an important clinical issue, and it may be instrumental in identifying high-
risk patients amenable to preventive measures and/or closer follow-up 
strategies as a part of the standard of care. Former clinical studies with 
functional PRR gene variants in cirrhosis primarily focused on the 
development of SBP in ascitic patients [8–11]. Distinctly, in the present study 
we comprehensively assessed the utility of various functional SNPs of three 
different PRR genes simultaneously in a large prospective cohort, comprising 
the whole severity spectrum of cirrhosis, with a special emphasis on the 
development of non-SBP type BI.  
 In our cohort, the frequencies of PRR gene variants were comparable 
within other cirrhotic patient cohorts and with healthy Caucasians [20,21]. 
 Similar to most of the previous studies [8–10], the presence of NOD2 
allele variants was a risk factor for SBP in our cohort as well. A recent large 
association study in patients with decompensated cirrhosis however, did not 
demonstrate a role of NOD2 variant in mediating susceptibility for SBP [23]. In 
our study development of SBP was not more frequent in patients with TLR2 (-
16934 T>A, rs4696480) and TLR4 (D299G, rs4986790) polymorphisms. This 
latter finding is a novelty. At the same time, the association of SBP with 
various TLR2 genotypes is somewhat controversial in the published literature. 
In the studies of Nischalke et al. [10] and Lutz et al. [22] TLR2 (-16934 TT) 
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genotype but not TLR2 R753Q and P631H mutations were associated with 
SBP. Contrarily, Bruns et al. showed that not TLR2 (-16934 T>A) but TLR2 
R753Q polymorphism increased the risk of SBP [11]. A limitation of our study 
compared to previous cohorts, was the relatively lower number of patients 
with ascites (n=88). The present study did not allow for an in-depth analysis of 
the association of PRR variants with different types of SBP (culture-negative, 
culture-positive or bacterascites), which is a drawback. Since there was 
twenty incident cases of SBP during follow-up and only half of them was 
cultured.  
 The PRR gene variants examined in our study were reported to have a 
special role in susceptibility to bacterial infections and sepsis in patients with 
acquired immune deficiency (i.e. acute leukaemia or allogeneic stem cell 
transplantation) [22,23]. Furthermore in critically ill patients, the NOD2/TLR4 
combination was associated with higher rate of bacteraemia [24]. In patients 
with advanced cirrhosis the TLR4 (D299G, rs4986790) variant was 
recognized to increase overall BI rates in a single retrospective study (n=111) 
[25]. At the same time, another TLR4 variant (c.+1196C/T, rs4986791) did not 
increase the risk of BI in a large retrospective cohort (n=336), including a 
validation cohort with same samples size [26]. In our study none of the 
examined PRR variants were associated with higher risk of non-SBP type BI.  
In spite of the known fact that two main members of the PRR family – TLRs 
and NOD like receptors – act synergistically in the initiation of host innate 
immune response to BI [27], neither of the NOD2, TLR2 and TLR4 gene 
variant combinations showed increased BI susceptibility. The limitation of the 
present study is that the association of bacterial infections and TLR4 
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polymorphisms warrants further evaluation in a larger cohort since our study 
was underpowered to detect such an association at this sample size 
(Supplementary Table 1). The limited number of incident cases the seven 
different location subgroups did not make possible a more subtle assessment 
of the potential role of PRR variants in the development of certain types of 
infection.  
 The strength of the present study is that the whole disease severity 
spectrum of cirrhosis was represented, allowing for an in-depth evaluation of 
the interaction of PRR gene variants and BI development in various disease 
severity subgroups. Cirrhosis associated immunodeficiency syndrome (CAID) 
is a dynamic process evolving with the natural history of progression to end 
stage liver disease [28]. Therefore, the impact of an inherited risk for a BI 
might be different in early vs. advanced cirrhosis, owing to limited 
compensatory mechanisms. However, PRR gene variants were not 
associated with a higher risk of non-SBP type BI in any subgroups of various 
disease severities. These results confirm that acquired immune deficiency 
state in cirrhosis is more dominant of a risk factor than the presence of 
functional genetic polymorphisms in the development of BI. 
 The most notable discovery of the present study was that a prior 
episode of BI was a risk factor for the development of a subsequent BI 
episode. This finding suggests the presence of further persistent host factors 
that modulate an individual’s susceptibility for BI. Interestingly, this association 
was present in early as well as in advanced disease stages. Remarkably, 
history of a prior BI episode and an advanced disease stage had similar 
impacts on the infectious risk.  
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 Pathological BT is associated with clinically relevant complications in 
cirrhosis [29]. There is evidence that variants of the NOD2 gene [30,31], and 
various TLR [32] polymorphisms contribute to BT in patients with Crohn’s 
diseases. Likewise in patients with decompensated cirrhosis an increased 
translocation of bacterial DNA fragments into ascitic fluid was found in the 
presence of the NOD2 risk variant p.G908R [33]. Moreover there was 
increased transition of pathologic BT to culture-positive SBP in the case of the 
same NOD2 variant [34,35]. Furthermore, TLR2 (-16934 T>A, rs4696480) 
and TLR4 (D299G, rs4986790) polymorphisms were associated with an 
increased systemic antigen burden as well, described by the serum level of 
lipoteichoic acid, LPS, and bacterial-DNA [32].  
 In our study we applied both serologic and clinical approaches to 
assess the impact of PRR genetic variants to BT. First, we examined the 
effect of NOD and TLR SNPs on the serological response to BT, but used 
different serologic markers than in the study of Piñero et al. [32]. The 
frequency of IgA type anti-microbial antibodies and LBP levels in our study did 
not differ between various PRR genotypes; neither in the entire cohort nor in 
the subgroup of patients with/ or without ascites.  Second, we hypothesised 
that if PRR genetic variants were linked to BT, they would be associated with 
enhanced diseases progression, e.g. the advent of first decompensating 
event, or liver-related death. In accordance with our serologic results, different 
polymorphisms of the NOD2 and TLR2 and TLR4 genes did not influence 
these adverse outcomes. It should be pointed out that our analysis is the first 
to consider the effect of PRR gene variants on the development of a 
decompensating event in cirrhosis.  
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The effect of PRR gene variants on mortality was assessed previously 
but yielded conflicting results. Appenrodt et al. found four-fold increased risk 
in cirrhotic patients with NOD2 risk alleles [9]. Concordantly to our findings 
Bruns et al. did not report an increased hazard of death related to the same 
variants of NOD2 [8]. 
 In conclusion, we were able to confirm the previous discovery that 
common NOD2 gene variants increased the risk of SBP. However, NOD2 and 
other SNPs of TLR2 and TLR4 did not influence the development of non-SBP 
type bacterial infections. Disease severity and a prior episode of bacterial 
infection were highly relevant clinical risk factors for a subsequent episode. 
PRR gene variants were neither associated with serological markers of 
bacterial translocation, nor were they associated with the development of 
clinical decompensation or liver-related death during follow-up. These results 
suggest a limited value of PRR genotyping in the prediction of a progressive 
disease course in cirrhosis.  
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ABSTRACT  
Background&Aims: Pattern recognition receptors (PRRs) have a key role in 
the innate host defense. Functional polymorphisms of various PRRs have 
been established to contribute to an increased susceptibility to spontaneous 
bacterial peritonitis (SBP). Their role in the development of cirrhosis-
associated bacterial infections (BI), beyond SBP or progressive disease 
course related to pathological bacterial translocation (BT) remains unknown. 
Methods: 349 patients with cirrhosis were genotyped for common NOD2 
(R702W, G908R and L1007PfsinsC), TLR2 (-16934T>A), and TLR4 (D299G) 
gene variants. Incidence of BIs, decompensating events (ascites, variceal 
bleeding and hepatic encephalopathy) and liver-related death were assessed 
in a 5-year follow-up observational study. Pathological BT was assessed 
based on the presence of anti-microbial antibodies or lipopolysaccharide-
binding protein (LBP) level. Results: In patients with ascites (n=88) only 
NOD2 gene variants were associated with an increased cumulative probability 
of SBP compared to wild-type (76.9%±19.9% vs. 30.9%±6.9%, 
PLogRank=0.047). Neither individual polymorphisms, nor combined PRR genetic 
profiles were associated with the risk of non-SBP type BI. Advanced disease 
stage (HR,[95%CI]: 2.11 [1.38-3.25]) and prior history of a BI episode (HR: 
2.42 [1.58-3.72]) were the major clinical risk factors of a subsequent BI. The 
risk of a non-SBP type BI in patients with advanced disease and a prior BI 
was even higher (HR: 4.74 [2.68-8.39]). The frequency of anti-microbial 
antibodies and LBP levels did not differ between various PRR genotypes. 
Correspondingly, PRR genetic profile was not able to predict the long-term 
disease course. Conclusions: In cirrhosis, functional polymorphisms of PRRs 
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did not improve the identification of patients with high risk of BI beyond SBP 
or progressive diseases course. 
 
Word count for abstract: 250 
Key words: pattern recognition receptors, genetic polymorphisms, cirrhosis, 
bacterial infection, complications, mortality 
 
Key Points 
• In this 5-year follow-up study, we evaluated the role of functional 
polymorphisms of various PRRs (NOD2, TLR2, and TLR4) in the 
development of bacterial infections, clinical decompensation and 
mortality in patients with cirrhosis. 
• We confirmed that NOD2 va iants were risk factors of SBP in patients 
with ascites.  
• Clinical factors (advanced disease and history of a bacterial infection)  
were major determinants of non-SBP type bacterial infections. 
• We found no association between PRR gene variants and serologic 
markers of pathological bacterial translocation. Concordantly, patients 
with PRR gene variants did not have an increased risk for clinical 
decompensation or mortality. 
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INTRODUCTION 
Pathological bacterial translocation (BT) is a characteristic feature of cirrhosis, 
mainly in the advanced disease stage, and it plays an essential role in the 
pathogenesis and the development of various complications of the disease. 
The most evidenced clinical consequence of BT is the spontaneous bacterial 
peritonitis (SBP) and bacteremia. [1] Systemic infections beyond SBP might 
also be related to BT. Even in the absence of an overt infection, sustained 
entry of various bacterial products into the hepato-splanchnic and systemic 
circulation can also have a deleterious effect by inducing an enhanced pro-
inflammatory response. Failure to control invading bacteria and/or their 
products, together with an increased host susceptibility to infection, may result 
in the damage of the remote organ. [2] Development of consequential organ 
failure(s) is a major determinant of mortality in this patient population. [3] 
 Accurate identification and risk stratification of BT can efficiently aid the 
preventive strategies against bacterial infections and other complications of 
cirrhosis. Direct data on culturable BT to mesenteric lymph nodes and 
upstream compartments is not available in humans. Recently, various 
serologic markers (e.g. lipopolysaccharide binding protein [LBP], [4] bacterial 
DNA [5] or IgA type anti-microbial antibodies [6,7]) have been proposed to 
reflect sustained gut microbial exposure. Additionally, susceptibility genes for 
pathological BT have also been revealed. Functional polymorphisms of 
pattern recognition receptors (PRRs) alter the detection and clearance of 
bacterial pathogens, thus influencing the innate host defence mechanisms. 
Single nucleotide polymorphisms (SNPs) in the promoter and the encoding 
regions of nucleotide-binding oligomerization domain (NOD) [8,9] or toll-like 
Page 48 of 78Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 6 
receptors (TLR) [10,11] were reported to increase the risk of SBP. However, 
their comprehensive evaluation regarding non-SBP type bacterial infections, 
or various other aspects of progressive disease course in cirrhosis has not 
been fully elucidated so far.  
 In the present study, we aimed to investigate the clinical importance of 
functional polymorphisms of various PRRs in a large cohort of patients with 
cirrhosis. In a 5-year follow-up observational study, we evaluated whether 
certain genetic variants of NOD2, TLR2 and TLR4 (1) constitute a risk for the 
development of SBP or non-SBP type bacterial infections; (2) can be linked to 
the established serologic markers of bacterial translocation; (3) constitute a 
risk for the progressive disease course, such as development of 
decompensation events (ascites formation, hepatic encephalopathy or 
variceal bleeding), or liver-related mortality.  
 
PATIENTS AND METHODS  
Study design  
We performed a cohort study among adult patients with an established 
diagnosis of cirrhosis of different etiologies, in a tertiary care referral center of 
Hungary (Division of Gastroenterology Department of Internal Medicine, 
Clinical Center, University of Debrecen). The present study population is a 
part of our entire patient cohort comprising a total of 404 patients with 
cirrhosis who were recruited consecutively between May 1, 2006 and 
December 31, 2010 from the outpatient clinic during regular, or extraordinary 
follow-up visits, and also from the inpatient ward, when hospitalized with an 
acute decompensation (AD) episode [12,13]. For the present study, blood 
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samples from 349 patients were available (243 outpatients and 106 
hospitalized subjects due to an AD episode) (Figure 1). Acute 
decompensation was defined by the acute development of large ascites 
(grade II/III) [14], acute hepatic encephalopathy [15], acute variceal bleeding 
[16] and/or the presence of systemic bacterial infection.  
 Clinical characteristics of patients at inclusion are presented in Table 1. 
Mean disease duration from diagnosis of cirrhosis was 3.9 ± 4.2 years among 
patients at the time of the inclusion. Blood samples, routine laboratory data 
and a detailed clinical phenotype were captured at inclusion. Clinical data was 
determined by an in-depth review of patients’ medical records using a 
structured interview. Medical records that documented age at diagnosis, 
etiology, presence of hepatocellular carcinoma, esophageal varices, 
extrahepatic co-morbidities, history of previous AD episode(s), and cirrhosis-
related medication were retrospectively analyzed for the period prior to the 
observational follow-up study. At enrollment, disease severity – assessed by 
liver-oriented scores (Child-Pugh and MELD) and clinical stage of the disease 
(compensated/ decompensated) – was always determined. 
 Outpatients at inclusion (n=243) were enrolled into an observational 
follow-up study where the attending gastroenterologist registered the date and 
type of bacterial infection (BI) warranting hospital admission (diagnostic 
criteria are summarized in Supplementary Material) and the development of 
disease specific complications (ascites, hepatic encephalopathy or variceal 
bleeding) during regular, and extraordinary, outpatient follow-up visits and 
inpatient stays in a prospective manner. In Hungary, a regular outpatient 
follow-up visit is usually scheduled for every 3 months at a specialized 
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gastroenterology center for patients with decompensated cirrhosis (a follow-
up between 1-3 months may be scheduled if dictated by disease severity or 
the presence of certain disease specific complications) and for up to 6 months 
for patients with cirrhosis but without a prior episode of AD. Follow-up period 
lasted for 5 years, or until death/loss of follow-up. Eighty-two (34%) patients 
died during follow-up, median time to death was 660 days (IQR: 304-977). In 
the 181 patients without death occurring, median follow-up lasted 1128 days 
(IQR: 469-1825). Collected data were transferred and stored in a database. At 
the end of the study period on December 31, 2013, all clinical data was 
extracted for further analysis.  
 
Gene analysis of NOD2, TLR2 and TLR4 
Genomic DNA was extracted from whole-blood samples using the Gentra 
Puregene Blood Kit (Qiagen; Hilden, Germany) following the manufacturer’s 
protocol. Three alleles of the NOD2 gene variants rs2066844, (p.R702W:, 
NM_022162.2:c.2104C>T), rs2066845 (p.G908R; NM_022162.2:c.2722G>C), 
and rs2066847 (L1007Pfs; NM_022162.2:c.3019dupC) were genotyped using 
hybridization probes on fluorescence resonance energy transfer (FRET) on a 
LightCycler 480 (Roche) real-time PCR system, according to Ferreiros-Vidal 
et al [17]. Gene variant of TLR2 gene rs4696480 (NM_003264.4:c.-
148+1614T>A) was also genotyped using oligonucleotides according to Oh et 
al. [18]. The gene variant of TLR4 gene rs4986790 (p.D299G; 
NM_138554.4:c.896A>G) was genotyped using self-designed amplification 
oligos (TLR4-D299G F: CATCGTTTGGTTCTGGGAG and TLR4-D299G R: 
TTTACCCTTTCAATAGTCACACTCA), while FRET oligonucleotides were 
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similar to Hamann et al. (TLR4-D299G SENS: 
CTACTACCTCGATGGTATTATTGACTTATT-6FAM, TLR4-D299G ANCH: 
Cy5.5 -AATTGTTTGACAAATGTTTCTTCATTTTCC-3’phosph) [19]. 
Representative melting curve genotyping results are shown in the 
Supplementary Figure 1. Genotyping was technically unsuccessful in two 
patient samples for NOD2 analysis, and in one sample for TLR2 and TLR4 
analysis. 
 
Serologic analysis 
Serum levels of total bilirubin, creatinine, and albumin, blood cell count and 
INR were determined by routine laboratory analysis. 
 Blood samples were obtained at enrollment from each patient and were 
frozen at -70°C until testing. All the serological assays were performed in a 
blinded fashion without prior knowledge of the patient’s clinical information. 
Commercially available sandwich enzyme-linked immunosorbent assays 
(ELISA) were used according to the manufacturer’s protocol to determine 
serologic markers of pathological BT, namely lipopolysaccharide-binding 
protein (LBP) (Hycult Biotechnology, Uden, Netherlands), endotoxin core IgA 
antibody (EndoCAb IgA) (Hycult Biotechnology, Uden, Netherlands) and anti-
OMP Plus IgA antibody (QUANTA Lite®, Inova Diagnostics, San Diego, CA). 
EndoCAb directs against a mixture of incomplete endotoxins of 4 different 
species (Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli 
and Klebsiella aerogenes), while anti-OMP Plus antibody does to a mixture of 
multiple bacterial proteins derived from two species of intestinal bacteria (one 
Gram-positive and one Gram-negative). Cut-off positivity was 195 AU/mL for 
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EndoCAb IgA, defined by our group previously [19] as a value exceeding the 
95th percentile level of the healthy control group, and 25 U for anti-OMP Plus 
IgA as recommended by the manufacturer.  
 
Ethical considerations 
The study protocol was approved by the Regional and Institutional Research 
Ethics Committee of University of Debrecen and by the National Scientific and 
Research Ethics Committee (DEOEC-RKEB/IKEB 5306-9/2011, 
3885/2012/EKU [60/PI/2012]). Each patient or legal surrogate was informed of 
the nature of the study and signed an informed consent form. 
 
Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous 
variables were summarized as means (standard deviation [SD]) or as 
medians (interquartile range [IQR, lowest 25%-highest 25%]) according to 
their homogeneity. Categorical variables were compared with Fisher’s exact 
test or χ
2 test with Yates correction, as appropriate. Continuous variables 
were compared with Mann-Whitney U test or Kruskal-Wallis H test with 
Dunn’s multiple comparison post hoc analysis. Allele frequencies of the 
respective SNPs were tested for deviations from the Hardy–Weinberg 
equilibrium and then compared for statistical differences with the Cochrane 
Armitage trend test (Helmholtz Center Munich, http://ihg.gsf.de/cgi-bin/hw/ 
hwa1.pl). Kaplan–Meier (KM) analysis was used to calculate the cumulative 
probability (CP) of adverse outcomes (development of non-SBP BI, SBP, 
decompensation event and mortality). Right censoring of patients was 
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performed in case of transplantation or loss of follow-up as appropriate. 
Differences in observed probabilities were assessed by the log-rank test. The 
association between categorical clinical variables, or different PRR 
genotypes, and adverse disease outcomes during follow-up was assessed by 
univariate Cox-regression analysis. Multivariate analyses were performed with 
a forward inclusion procedure and a likelihood ratio test to identify 
independent predictors. Binary logistic regression was used to assess the 
infection-related mortality at 28 and 90 days. Associations are given as a 
hazard ratio [HR] or odds ratio [OR] with 95% confidence intervals [CI]. For 
statistical analysis and graphical presentation, the SPSS 24.0 [SPSS, 
Chicago, IL], and GraphPad Prism 6 programs were used. A 2-sided 
probability value of <0.05 was considered statistically significant.  
 
RESULTS 
 
Genotype distribution of various functional polymorphisms of PRRs in 
cirrhosis  
Frequencies of various PRR genotypes in cirrhosis are summarized in Table 
2. None of the examined NOD2, TLR2 and TLR4 gene variants was different 
between outpatients and patients with AD. Further analysis of clinical and 
laboratory characteristics of outpatients revealed that age, gender, presence 
of a co-morbidity or HCC, etiology or severity of cirrhosis was not different 
across the various PRR genotype subgroups. Co-medications at enrolment 
comprising the use of proton pump inhibitor (PPI), non-selective beta blocker 
(NSSB) and secondary antibiotic prophylaxis either norfloxacin for prevention 
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of SBP or rifaximin for prevention of HE were also not different among 
patients with genetic variants of NOD2, TLR2 and TLR4 and with wilde-type 
(Table 1).  
 
Risk factors of non-SBP type BI  
Eighty-five (35.0%) of the included outpatients encountered a non-SBP type 
BI episode during the follow-up period. The median time to development of a 
first BI episode was 581 (207-803) days. Urinary tract infection was the most 
commonly diagnosed BI, and accounted for 43.5% (n=37) of the events. 
Other sites of BI were as follows: pneumonia (18.8%), erysipelas (10.6%), 
acute bronchitis (5.9%), cholangitis (3.5%), bacteremia (3.5%), gastroenteritis 
(1.2%) and unidentified in 9 (10.6%) cases. 2.4% of the cases were multifocal. 
Microbiological analysis was performed in 35 (41.2%) cases. Bacteria were 
Gram-negative in 76.5% and Gram-positive in 23.5% of culture positive cases 
(n=17) (Supplementary Material).  
 
Functional polymorphisms of PRR genes  
Patients with any risk variants in NOD2, TLR2 or TLR4 genes did not have an 
increased cumulative probability of a non-SBP type BI episode during follow-
up (Figure 2A), not even when stratifying according to presence of ascites 
(Figure 2B). Patients carrying both a TLR2 variant and at least one NOD2 
risk variant (n=10) had also a similar rate of non-SBP type BI, than patients 
not carrying both variants (PLogRank=0.397). There was no rationale for testing 
the potential effect of the TLR4 and NOD2 variant combination. Only one 
patient carried both variant genotypes. 
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 The presence or absence of a NOD2, TLR2 or TLR4 variants did not 
affect the type of pathogen causing BI (Gram-negative or –positive), or the 
location of BI. 
 Furthermore, these PRR gene variants were not associated with the 
risk of mortality during a subsequent bacterial infection (Supplementary 
Table 2).  
  
Clinical co-variates 
Of the clinical factors: co-morbidity, PPI use, prior history of a BI episode and 
advanced disease stage were all associated with an increased cumulative 
probability of non-SBP type BI episodes during the follow-up period (Table 3).  
Of the patients with a prior history of BI, 66.5%±6.3% (standard error) 
developed another BI episode, compared to 39.7%±5.1 % of those with no 
such history (PLogRank:<0.001). Regarding advanced disease stage, similar 
results were found if advanced disease stage was depicted either by the 
presence of ascites (65.2%±6.6% vs. 42.0%±5.1%, PLogRank:<0.001), Child-
Pugh stage B/C (68%±6.1% vs. 38.1%±5.2%, PLogRank:<0.001) or by 
decompensated clinical stage (58.8%±5.7% vs. 40.8%±5.8%, PLogRank=0.01).  
The combination of these two relevant clinical factors revealed important 
findings. First, prior history of a BI episode significantly increased the 
probability of the subsequent development of another BI event, regardless of 
disease severity. Furthermore, a prior history of a BI without ascites was 
associated with the same cumulative probability of a BI occurring, as the 
presence of ascites without prior history of a BI (57.3%±8.7% and 
51.0%±9.9%, respectively). The combined presence of both clinical risk 
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factors resulted in an even higher cumulative probability of BI (80.3%±7.7%) 
(Figure 3 and Table 3). 
 
Multivariate analysis  
Multivariate Cox-regression analysis and the forward inclusion procedure, 
taking all significant clinical co-variates of univariate analysis into account, 
indicated that presence of ascites (HR [95%CI]: 1.71 [1.08-2.7], higher MELD 
score (1.08 [1.02-1.15]) and prior BI episode (2.02 [1.3-3.14]) were 
independently associated with the risk of a non-SBP type BI development 
during follow-up. 
 
Risk factors of SBP  
Of the patients with ascites 22.7% (20/88) developed community acquired 
SBP during the follow-up period. Of the cases with microbiological 
investigation, 36.4% (4/11) was culture-positive SBP, while 63.6% (7/11) was 
culture negative. Bacteria were Gram-negative in 75% and Gram-positive in 
25% of culture positive cases (Supplementary Material). The median time to 
the development of SBP was 340 (126-662) days. The presence of NOD2 risk 
allele variants, but not of TLR2 and TLR4 variants, were associated with an 
increased cumulative probability of SBP (Figure 4). Of the patients with any 
NOD2 risk variants 76.9%±19.9% developed SBP, compared to 30.9%±6.9% 
of those with NOD2 wild type (PLogRank=0.047). Patients with or without any 
NOD2 risk allele variants had similar MELD scores (median [IQR]: 14 [9-16] 
vs. 13 [10-15], respectively, P=0.874). Prior SBP episode was also associated 
with the risk of SBP development (PLogRank=0.048). 
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Association of functional polymorphisms of PRR genes with serologic 
markers of BT 
Serum level of LBP and frequencies of IgA type antibodies directed against 
various gut microbial components (anti-OMP Plus and EndoCab) were not 
different according to the examined PRR genotypes (Table 4). 
 
Functional polymorphisms of PRR genes and development of 
decompensation events 
Of the patients with a compensated clinical stage at enrolment 31.4% 
(38/121) developed any type of decompensation event (ascites, variceal 
bleeding or hepatic encephalopathy). The median time to the development of 
a first decompensation was 540 (140-913) days. Neither NOD2 risk variants 
(PLogRank=0.681) nor TLR2 and TLR4 polymorphisms (PLogRank= 0.068 and 
0.249) were risk factors of clinical decompensation (Supplementary Figure 
2). 
 
Functional polymorphisms of PRR genes and survival 
In the total cohort, liver-related death occurred in 82 (33.7%) subjects. Median 
time to mortality was 660 (304-977) days. Kaplan-Meier survival analysis 
demonstrated a significantly worse survival in patients with advanced disease 
according to presence of ascites (PLogRank<0.001), Child-Pugh stage B/C 
(PLogRank<0.001), or decompensated clinical stage (PLogRank=0.033) and prior 
BI episode (PLogRank=0.050). Neither NOD2 risk variants (PLogRank= 0.785) nor 
TLR2 and TLR4 polymorphisms (PLogRank= 0.682 and 0.732) were associated 
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with overall survival (Supplementary Figure 3). 
 
DISCUSSION 
 Bacterial infections beyond SBP have significant prognostic 
implications in patients with cirrhosis [1]. Thus, individual risk stratification for 
BI is an important clinical issue, and it may be instrumental in identifying high-
risk patients amenable to preventive measures and/or closer follow-up 
strategies as a part of the standard of care. Former clinical studies with 
functional PRR gene variants in cirrhosis primarily focused on the 
development of SBP in ascitic patients [8–11]. Distinctly, in the present study 
we comprehensively assessed the utility of various functional SNPs of three 
different PRR genes simultaneously in a large prospective cohort, comprising 
the whole severity spectrum of cirrhosis, with a special emphasis on the 
development of non-SBP type BI.  
 In our cohort, the frequencies of PRR gene variants were comparable 
within other cirrhotic patient cohorts and with healthy Caucasians [20,21]. 
 Similar to most of the previous studies [8–10], the presence of NOD2 
allele variants was a risk factor for SBP in our cohort as well. A recent large 
association study in patients with decompensated cirrhosis however, did not 
demonstrate a role of NOD2 variant in mediating susceptibility for SBP [23]. In 
our study development of SBP was not more frequent in patients with TLR2 (-
16934 T>A, rs4696480) and TLR4 (D299G, rs4986790) polymorphisms. This 
latter finding is a novelty. At the same time, the association of SBP with 
various TLR2 genotypes is somewhat controversial in the published literature. 
In the studies of Nischalke et al. [10] and Lutz et al. [22] TLR2 (-16934 TT) 
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genotype but not TLR2 R753Q and P631H mutations were associated with 
SBP. Contrarily, Bruns et al. showed that not TLR2 (-16934 T>A) but TLR2 
R753Q polymorphism increased the risk of SBP [11]. A limitation of our study 
compared to previous cohorts, was the relatively lower number of patients 
with ascites (n=88). The present study did not allow for an in-depth analysis of 
the association of PRR variants with different types of SBP (culture-negative, 
culture-positive or bacterascites), which is a drawback. Since there was 
twenty incident cases of SBP during follow-up and only half of them was 
cultured.  
 The PRR gene variants examined in our study were reported to have a 
special role in susceptibility to bacterial infections and sepsis in patients with 
acquired immune deficiency (i.e. acute leukaemia or allogeneic stem cell 
transplantation) [22,23]. Furthermore in critically ill patients, the NOD2/TLR4 
combination was associated with higher rate of bacteraemia [24]. In patients 
with advanced cirrhosis the TLR4 (D299G, rs4986790) variant was 
recognized to increase overall BI rates in a single retrospective study (n=111) 
[25]. At the same time, another TLR4 variant (c.+1196C/T, rs4986791) did not 
increase the risk of BI in a large retrospective cohort (n=336), including a 
validation cohort with same samples size [26]. In our study none of the 
examined PRR variants were associated with higher risk of non-SBP type BI.  
In spite of the known fact that two main members of the PRR family – TLRs 
and NOD like receptors – act synergistically in the initiation of host innate 
immune response to BI [27], neither of the NOD2, TLR2 and TLR4 gene 
variant combinations showed increased BI susceptibility. The limitation of the 
present study is that the association of bacterial infections and TLR4 
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polymorphisms warrants further evaluation in a larger cohort since our study 
was underpowered to detect such an association at this sample size 
(Supplementary Table 1). The limited number of incident cases the seven 
different location subgroups did not make possible a more subtle assessment 
of the potential role of PRR variants in the development of certain types of 
infection.  
 The strength of the present study is that the whole disease severity 
spectrum of cirrhosis was represented, allowing for an in-depth evaluation of 
the interaction of PRR gene variants and BI development in various disease 
severity subgroups. Cirrhosis associated immunodeficiency syndrome (CAID) 
is a dynamic process evolving with the natural history of progression to end 
stage liver disease [28]. Therefore, the impact of an inherited risk for a BI 
might be different in early vs. advanced cirrhosis, owing to limited 
compensatory mechanisms. However, PRR gene variants were not 
associated with a higher risk of non-SBP type BI in any subgroups of various 
disease severities. These results confirm that acquired immune deficiency 
state in cirrhosis is more dominant of a risk factor than the presence of 
functional genetic polymorphisms in the development of BI. 
 The most notable discovery of the present study was that a prior 
episode of BI was a risk factor for the development of a subsequent BI 
episode. This finding suggests the presence of further persistent host factors 
that modulate an individual’s susceptibility for BI. Interestingly, this association 
was present in early as well as in advanced disease stages. Remarkably, 
history of a prior BI episode and an advanced disease stage had similar 
impacts on the infectious risk.  
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 Pathological BT is associated with clinically relevant complications in 
cirrhosis [29]. There is evidence that variants of the NOD2 gene [30,31], and 
various TLR [32] polymorphisms contribute to BT in patients with Crohn’s 
diseases. Likewise in patients with decompensated cirrhosis an increased 
translocation of bacterial DNA fragments into ascitic fluid was found in the 
presence of the NOD2 risk variant p.G908R [33]. Moreover there was 
increased transition of pathologic BT to culture-positive SBP in the case of the 
same NOD2 variant [34,35]. Furthermore, TLR2 (-16934 T>A, rs4696480) 
and TLR4 (D299G, rs4986790) polymorphisms were associated with an 
increased systemic antigen burden as well, described by the serum level of 
lipoteichoic acid, LPS, and bacterial-DNA [32].  
 In our study we applied both serologic and clinical approaches to 
assess the impact of PRR genetic variants to BT. First, we examined the 
effect of NOD and TLR SNPs on the serological response to BT, but used 
different serologic markers than in the study of Piñero et al. [32]. The 
frequency of IgA type anti-microbial antibodies and LBP levels in our study did 
not differ between various PRR genotypes; neither in the entire cohort nor in 
the subgroup of patients with/ or without ascites.  Second, we hypothesised 
that if PRR genetic variants were linked to BT, they would be associated with 
enhanced diseases progression, e.g. the advent of first decompensating 
event, or liver-related death. In accordance with our serologic results, different 
polymorphisms of the NOD2 and TLR2 and TLR4 genes did not influence 
these adverse outcomes. It should be pointed out that our analysis is the first 
to consider the effect of PRR gene variants on the development of a 
decompensating event in cirrhosis.  
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The effect of PRR gene variants on mortality was assessed previously 
but yielded conflicting results. Appenrodt et al. found four-fold increased risk 
in cirrhotic patients with NOD2 risk alleles [9]. Concordantly to our findings 
Bruns et al. did not report an increased hazard of death related to the same 
variants of NOD2 [8]. 
 In conclusion, we were able to confirm the previous discovery that 
common NOD2 gene variants increased the risk of SBP. However, NOD2 and 
other SNPs of TLR2 and TLR4 did not influence the development of non-SBP 
type bacterial infections. Disease severity and a prior episode of bacterial 
infection were highly relevant clinical risk factors for a subsequent episode. 
PRR gene variants were neither associated with serological markers of 
bacterial translocation, nor were they associated with the development of 
clinical decompensation or liver-related death during follow-up. These results 
suggest a limited value of PRR genotyping in the prediction of a progressive 
disease course in cirrhosis.  
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Table 1. Epidemiological, clinical and laboratory characteristics of outpatients with cirrhosis at enrolment according to 
different pattern recognition receptors genetic variants 
 
 
Total NOD2 polymorphism
b
 
TLR2 16934T>A 
polymorphism 
rs4696480 
TLR4 D299G  
polymorphism 
rs4986790
×
 
 
 
(N=243)* 
Wild type  
(N=204) 
Risk allele 
(N=37) 
P-value 
TT 
(N=64) 
TA 
(N=104) 
AA 
(N=74) 
P-value 
AA 
(N=225) 
AG 
(N=17) 
P-value 
Age, years
a
 
56 
(50-63) 
55 
(49-63) 
59 
(53-65) 
0.082 
55 
(51-63) 
57 
(50-65) 
55 
(49-63) 
0.172 
56 
(50-64) 
53 
(49-56) 
0.151 
Male sex 
52.3% 
(127) 
51.5% 
(105) 
54.1% 
(20) 
0.772 
56.3% 
(36) 
54.8% 
(57) 
44.6% 
(33) 
0.299 
52.4% 
(118) 
47.1% 
(8) 
0.668 
Alcoholic etiology  
62.6% 
(152) 
61.3% 
(125) 
67.6% 
(25) 
0.468 
65.6% 
(42) 
66.3% 
(69) 
54.1% 
(40) 
0.205 
62.7% 
(141) 
58.8% 
(10) 
0.752 
Child-Pugh 
stage 
A 
56.4% 
(137) 
55.9% 
(114) 
59.5% 
(22) 
0.671 
53.1% 
(34) 
53.8% 
(56) 
63.5% 
(47) 
0.194 
56.4% 
(127) 
58.8% 
(10) 
0.479 B 
37.9% 
(92) 
37.7% 
(77) 
37.8% 
(14) 
37.5% 
(24) 
43.3% 
(45) 
29.7% 
(22) 
38.2% 
(86) 
29.4% 
(5) 
C 
5.8% 
(14) 
6.4% 
(13) 
2.7% 
(1) 
9.4% 
(6) 
2.9% 
(3) 
6.8% 
(5) 
5.3% 
(12) 
11.8% 
(2) 
MELD score
a
 
11 
(8-14) 
11 
(8-14) 
10 
(7-14) 
0.249 
11 
(8-14) 
11 
(8-14) 
11 
(8-14) 
0.689 
11 
(8-14) 
13 
(8-15) 
0.513 
Ascites 
36.2% 
(88) 
36.3% 
(74) 
35.1% 
(13) 
0.894 
35.9% 
(23) 
39.4% 
(41) 
31.1% 
(23) 
0.520 
35.6% 
(80) 
41.2% 
(7) 
0.641 
Decompensated stage 
50.2% 
(122) 
49.0% 
(100) 
56.8% 
(21) 
0.386 
54.7% 
(35) 
50.0% 
(52) 
45.9% 
(34) 
0.592 
49.8% 
(112) 
52.9% 
(9) 
0.801 
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Prior VB 
24.3% 
(59) 
23.0% 
(47) 
29.7% 
(11) 
0.381 
29.7% 
(19) 
21.2% 
(22) 
23.0% 
(17) 
0.440 
22.7% 
(51) 
41.2% 
(7) 
0.085 
Prior BI 
38.7% 
(94) 
37.7% 
(77) 
40.5% 
(15) 
0.747 
42.2% 
(27) 
35.6% 
(37) 
39.2% 
(29) 
0.685 
37.8% 
(85) 
47.1% 
(8) 
0.448 
Prior SBP 
9.5% 
(23) 
8.8% 
(18) 
13.5% 
(5) 
0.372 
6.3% 
(4) 
13.5% 
(14) 
6.8% 
(5) 
0.189 
9.3% 
(21) 
11.8% 
(2) 
0.742 
Prior non-SBP type BI 
34.2% 
(83) 
34.3% 
(70) 
29.7% 
(11) 
0.587 
39.1% 
(25) 
28.8% 
(30) 
36.5% 
(27) 
0.338 
33.3% 
(75) 
41.2% 
(7) 
0.510 
Comorbidity 
53.9% 
(131) 
52.5% 
(107) 
59.5% 
(22) 
0.432 
62.5% 
(40) 
53.8% 
(56) 
45.9% 
(34) 
0.151 
55.1% 
(124) 
35.3% 
(6) 
0.114 
HCC 
9.9% 
(24) 
9.3% 
(19) 
13.5% 
(5) 
0.433 
10.9% 
(7) 
8.7% 
(9) 
10.8% 
(8) 
0.849 
10.2% 
(23) 
5.9% 
(1) 
0.564 
Creatinine (µmol/L)
a
 
67 
(54-84) 
66 
(55-82) 
71 
(52-98) 
0.513 
66 
(57-89) 
64 
(53-83) 
70 
(56-84) 
0.872 
66 
(54-83) 
72 
(55-85) 
0.680 
Bilirubin (µmol/L)
a
 
26 
(16-41) 
27 
(16-43) 
22 
(15-34) 
0.278 
27 
(16-43) 
23 
(14-43) 
28 
(17-39) 
0.529 
26 
(16-41) 
29 
(13-42) 
0.693 
INR
a
 
1.2 
(1.1-1.3) 
1 
(1.1-1.3) 
1 
(1.1-1.2) 
0.074 
1 
(1.1-1.4) 
1 
(1.1-1.3) 
1 
(1.1-1.3) 
0.514 
1 
(1.1-1.3) 
1 
(1.1-1.4) 
0.204 
Albumin (g/L)
a
 
38 
(33-42) 
37 
(32.5-42) 
39 
(34-43) 
0.332 
37 
(33-42) 
37 
(32-42) 
38 
(34-42) 
0.261 
37 
(33-42) 
37 
(29.5-44.5) 
0.944 
Leucocyte (G/L)
a
 
5.4 
(4.3-7.1) 
5.4 
(4.3-7.2) 
5 
(4.1-6.3) 
0.246 
6 
(4.3-7.1) 
5 
(4.3-7.3) 
5 
(4-6.9) 
0.452 
5 
(4.3-7.1) 
5 
(4.1-7.6) 
0.868 
Platelet (G/L)
a 
 
116 
(76-171) 
114 
(75-172) 
116 
(93-158) 
0.787 
125 
(80-170) 
112 
(76-182.5) 
112 
(72-163) 
0.504 
117 
(78.5-170) 
87 
(66-171) 
0.258 
NSBB use 
47.7% 
(116) 
48.0% 
(98) 
43.2% 
(16) 
0.591 
53.1% 
(34) 
47.1% 
(49) 
43.2% 
(32) 
0.508 
46.7% 
(105) 
58.8% 
(10) 
0.333 
PPI use 
44.9% 
(109) 
44.6% 
(91) 
43.2% 
(16) 
0.878 
46.9% 
(30) 
41.3% 
(43) 
47.3% 
(35) 
0.671 
45.3% 
(102) 
35.3% 
(6) 
0.422 
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Secondary antibiotic prophylaxis           
Norfloxacin for prevention of SBP 
9.5% 
(23) 
8.8% 
(18) 
13.5% 
(5) 
0.372 
6.3% 
(4) 
13.5% 
(14) 
6.8% 
(5) 
0.189 
9.3% 
(21) 
11.8% 
(2) 
 
0.742 
Rifaximin for prevention of HE 
5.8% 
(14) 
5.4% 
(11) 
8.1% 
(3) 
0.457 
7.8% 
(5) 
3.8% 
(4) 
6.8% 
(5) 
0.515 
5.8% 
(13) 
5.9% 
(1) 
0.986 
 
BI, bacterial infection; HCC, hepatocellular carcinoma; HE: hepatic encephalopathy; INR, international normalized ratio; NSSB, non-
selective beta blocker; 
PPI, proton pump inhibitor; SBP, spontaneous bacterial peritonitis; VB: variceal bleeding;  
*NOD2 genotype were technically unsuccessful in 2 cases, while TLR2 and TLR4 for 1 case. 
a median, IQR (lowest 25%-highest 25%) p values were calculated with Mann-Whitney U-test, χ
2
-test or Fisher’s exact test as 
appropriate 
b NOD2 risk variants were the followings: R702W C>T, rs2066844; G908R G>C, rs2066845 and L1007fsinsC -/C, rs2066847 
× No cases with GG genotype of TLR4 D299G polymorphism were detected in outpatients 
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Table 2. Genotype distribution of functional polymorphisms of various pattern recognition 
receptors in patients with cirrhosis  
 
  Total  
cohort 
Outpatients Acute  
Decompensation 
  n % n % n % 
NOD2 L1007fsinsC -/C,  
rs2066847a 
-/- 326 93.9% 226 93.8% 100 94.3% 
-/C 21 6.1% 15 6.2% 6 5.7% 
NOD2 R702W C>T,  
rs2066844a 
CC 318 91.6% 220 91.3% 98 92.5% 
CT 29 8.4% 21 8.7% 8 7.5% 
NOD2 G908R G>C,  
rs2066845a 
GG 338 97.4% 238 98.8% 100 94.3% 
GC 9 2.6% 3 1.2% 6 5.7% 
NOD2 polymorphismb wild type 290 83.6% 204 84.6% 86 81.1% 
variant 57 16.4% 37 15.4% 20 18.9% 
TLR2 (-16934T>A) 
rs4696480 
TT 86 24.8% 64 26.4% 22 21.0% 
TA 154 44.4% 104 43.0% 50 47.6% 
AA 107 30.8% 74 30.6% 33 31.4% 
TLR4 D299G  
rs4986790 
AA 323 93.1% 225 93.0% 98 93.3% 
AG 23 6.6% 17 7.0% 6 5.7% 
GG 1 0.3% 0 0.0% 1 1.0% 
 
a No homozygote mutant was found 
b 2 patients were compound heterozygotes 
NOD2 genotype were technically unsuccessful in 2 cases, while TLR2 and TLR4 for 1 case. 
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Table 3. Association of clinical factors with the development of non- spontaneous bacterial peritonitis 
type bacterial infections. 
Non-SBP type BI development Univariate Cox regression 
n of  
subjects 
n of  
events 
CP of  
BI ± SE 
P- 
value* HR 95%CI 
P- 
value 
Total cohort 243 85 49.6±4.1     
Age <65 198 65 46.1±4.5 0.039 1.02 (1 - 1.04) 0.045 
≥65 45 20 66.9±10.2     
Gender male 116 39 44.8±5.6 0.486 1.16 (0.76 - 1.78) 0.487 
female 127 46 54.7±6.0     
Comorbidity absent 112 34 41.5±5.8 0.38 1.58 (1.02 - 2.44) 0.04 
present 131 51 57.8±5.8     
HCC absent 219 79 49.2±4.2 0.542 1.3 (0.56 – 3) 0.543 
present 24 6 40.8±15.6     
Etiology other 91 25 40.5±6.8 0.083 1.51 (0.94 - 2.4) 0.085 
alcoholic 152 60 54.6±5.1     
Clinical stage compensated 121 35 40.8±5.8 0.01 1.76 (1.14 - 2.71) 0.011 
decompensated 122 50 58.8±5.7     
Child-Pugh 
stage 
A 137 38 38.1±5.2 <0.001 2.6 (1.68 - 3.98) <0.001 
B/C 106 47 68.0±6.1     
Ascites absent 155 47 42.0±5.1 <0.001 2.11 (1.38 - 3.25) 0.001 
present 88 38 65.2±6.6     
MELD score (per 1 point increase) - - - - 1.12 (1.06-1.19) <0.001 
Prior BI absent 149 38 38.5±5.2 <0.001 2.42 (1.58 - 3.72) <0.001 
present 94 47 66.4±6.2     
Ascites + 
Prior BI 
none 100 24 33.7±6 <0.001 ref.   
either 104 37 54.6±6.5  1.86 (1.11-3.11) 0.018 
both 39 24 80.3±7.7  4.74 (2.68-8.39) <0.001 
Prior SBP absent 220 75 49.0±4.3 0.108 1.71 (0.88 - 3.31) 0.112 
present 23 10 52.5±12.0     
Prior non-SBP  
type BI 
absent 160 42 39.7±5.1 <0.001 2.26 (1.48 - 3.46) <0.001 
present 83 43 66.5±6.3     
NSBB use no 127 39 44.0±5.7 0.084 1.45 (0.95 - 2.23) 0.086 
yes 116 46 55.9±5.8     
PPI use no 134 37 40.2±5.5 0.006 1.81 (1.18 - 2.78) 0.007 
yes 109 48 60.5±5.9     
Secondary antibiotic prophylaxis        
Norfloxacin for  
prevention of SBP 
no 220 75 49.0±4.3 0.108 1.71 (0.88 - 3.31) 0.112 
yes 23 10 52.5±12.0     
Rifaximin for 
prevention of HE 
no 229 78 48.3±4.2 0.109 1.86 (0.86-4.04) 0.115 
yes 14 7 80.4±16.1     
*P-values of the log-rank tests; 
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CP, cumulative probability (Kaplan-Meier estimates);  CI, confidence interval;  HE: hepatic 
encephalopathy; HR: hazard ratio, BI; bacterial infection;  SBP, spontaneous bacterial peritonitis;  SE: 
standard error; HCC, hepatocellular carcinoma,  NSBB, non-selective beta blocker; PPI, proton pump 
inhibitor 
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Table 4. Association between serologic markers of bacterial translocation and various pattern recognition receptor 
genotypes 
 
NOD2 polymorphisma 
TLR2 16934T>A 
polymorphism 
rs4696480 
TLR4 D299G  
polymorphism 
rs4986790 
 Wild type  
(N=204) 
Risk allele 
(N=37) 
P- 
value 
TT 
(N=64) 
TA 
(N=104) 
AA 
(N=74) 
P- 
value 
AA 
(N=225) 
AG 
(N=17) 
P- 
value 
EndoCab IgA  50.0% 
(96) 
46.9% 
(15) 
0.743 59.7% 
(37) 
48.5% 
(47) 
42.4% 
(28) 
0.140 49.0% 
(102) 
58.8% 
(10) 
0.438 
OMP IgA  60.9% 
(106) 
61.5% 
(16) 
0.952 68.5% 
(37) 
61.8% 
(55) 
53.4% 
(31) 
0.259 61.7% 
(116) 
53.8% 
(7) 
0.574 
LBP (mg/L)b 17.5 
(12.4 - 24.3) 
17.9 
(12.7 - 34.6) 
0.454 17.8 
(12.1 - 27) 
18.6 
(12.8 - 25) 
17.1 
(12.2 - 27.6) 
0.977 17.8 
(12.8 - 27) 
15.92 
(9.4 - 23) 
0.378 
 
a 
NOD2 risk variants were the followings: R702W C>T, rs2066844; G908R G>C, rs2066845 and L1007fsinsC -/C, rs2066847 
b median, IQR (lowest 25%-highest 25%)  
P-values were calculated with Mann-Whitney U-test, χ
2
-test or Fisher’s exact test as appropriate  
NOD2 genotype were technically unsuccessful in 2 cases, while TLR2 and TLR4 for 1 case. 
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Figure legends 
 
Figure 1. Flowchart of the patients with cirrhosis in the cohort study 
AD: acute decompensation 
 
Figure 2. Development of non-spontaneous bacterial peritonitis type bacterial infections 
according to various pattern recognition genotypes in outpatients. Common NOD2 risk variants 
(L1007fsinsC -/C, R702W C>T or G908R G>C) and TLR2 (-16934T>A) or TLR4 (D299G) 
polymorphisms were not associated with the risk of non-SBP type BI development either in the entire 
cohort (A) or in subgroups according to ascites (B). 
 
Figure 3. Development of non-spontaneous bacterial peritonitis type bacterial infections 
according to clinical factors in outpatients. Prior history of a bacterial infection significantly 
increased the probability of the development of another bacterial infection episode during the follow-
up independently of disease severity (presence or absence of ascites). 
 
Figure 4. Development of spontaneous bacterial peritonitis according to various pattern 
recognition receptor genotypes in stable outpatients with cirrhosis. Any NOD2 risk variants 
(L1007fsinsC -/C, R702W C>T or G908R G>C) but not the TLR2 (-16934T>A) or TLR4 (D299G) 
polymorphisms were associated with the risk of SBP development.  
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Flowchart of the patients with cirrhosis in the cohort study  
AD: acute decompensation  
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Development of non-spontaneous bacterial peritonitis type bacterial infections according to various pattern 
recognition genotypes in outpatients. Common NOD2 risk variants (L1007fsinsC -/C, R702W C>T or G908R 
G>C) and TLR2 (-16934T>A) or TLR4 (D299G) polymorphisms were not associated with the risk of non-SBP 
type BI development either in the entire cohort (A) or in subgroups according to ascites (B).  
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Development of non-spontaneous bacterial peritonitis type bacterial infections according to clinical factors in 
outpatients. Prior history of a bacterial infection significantly increased the probability of the development of 
another bacterial infection episode during the follow-up independently of disease severity (presence or 
absence of ascites).  
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Development of spontaneous bacterial peritonitis according to various pattern recognition receptor 
genotypes in stable outpatients with cirrhosis. Any NOD2 risk variants (L1007fsinsC -/C, R702W C>T or 
G908R G>C) but not the TLR2 (-16934T>A) or TLR4 (D299G) polymorphisms were associated with the risk 
of SBP development.  
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